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ABSTRACT 
A majority of kinase inhibitors predominantly occupy the highly conserved adenine-
binding pocket located in the kinase catalytic cleft, and therefore the target selectivity of these 
molecules is a major concern.  In order to design highly specific next-generation drugs, it is 
essential to exploit the less-conserved binding pockets, which lie adjacent to the adenine-
binding pocket. Small peptides that can function as adenosine triphosphate (ATP) competitive 
inhibitors would prove useful in identifying and validating new druggable surfaces in the 
kinase catalytic cleft. These peptides, being larger than small molecules, have the potential to 
target the ATP binding pocket as well as surfaces that lie adjacent to this pocket. Such peptides 
recognizing novel binding pockets can assist the drug discovery process in several ways.  
In this thesis, we describe the isolation and characterization of a novel class of cyclic 
peptides, referred to as lariats, against Abl kinase, a drug target important in chronic myeloid 
leukemia and other disorders. Using a yeast two-hybrid approach, we first isolated two related 
lariats, named A1 and A2, from a pool of five million lariats, which interact with the catalytic 
domain of Abl kinase. In vitro studies indicated that the synthetic A1 lariat competitively 
inhibits ATP binding by targeting the catalytic cleft that lies between the N- and C- lobes of the 
kinase catalytic domain. To obtain tighter-binding variants of the A1 lariat, we developed an 
affinity maturation protocol consisting of two steps. In the first step, we defined acceptable and 
tolerable substitutions at each position of the A1 lariat using site-saturation mutagenesis (SSM). 
In the second step, we designed specific mutations to the A1 lariat based on the SSM results 
and evolved higher affinity variants. Synthetic and recombinant higher affinity lariats exhibited 
a strong inhibition of Abl kinase activity in vitro and Bcr-Abl kinase activity in vivo, 
respectively, illustrating the potential of lariats as chemical genetic tools. Resistance mutation 
profiling showed that the lariats are not affected by the activating mutations located in the 
activation loop of kinase, and instead bind preferentially to the kinase active conformation.  
Selectivity analysis indicated that the lariats do not recognize Src family kinases, which share a 
high structural similarity with Abl kinase in their active conformation. These findings, coupled 
with preliminary results from modeling studies, strongly suggest that the lariats have identified 
novel allosteric drug-binding pockets in the kinase catalytic cleft. 
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1. Introduction 
Protein kinases are implicated in more than 400 human diseases, directly or indirectly, 
and hence considered to be the most important group of drug targets in drug discovery 
programs (Melnikova and Golden, 2004).  Currently, a large number of small molecule kinase 
inhibitors are in various phases of development and in clinical trials, with 11 approved for 
clinical use by U. S. Food and Drug Administration (FDA) (Krishnamurthy and Maly, 2010). 
The vast majority of kinase inhibitors predominantly occupy the highly conserved adenine-
binding pocket located in the kinase catalytic cleft, and therefore the target selectivity of these 
molecules is a major concern.  In order to design highly specific next-generation drugs, it is 
essential to exploit the less-conserved binding pockets, which lie adjacent to the adenine-
binding pocket (Noble et al., 2004; Zhang et al., 2009). 
Various computational and experimental approaches (Coleman et al., 2006; Landon et 
al., 2007; Brenke et al., 2009; Ivetac et al., 2010) can be used to identify and characterize 
allosteric drug binding pockets in the kinase catalytic cleft. However, conventionally, the 
search for allosteric pockets has involved high-throughput screening (HTS) of small molecule 
libraries against purified kinase domains, followed by intensive kinetic and structural 
characterization. Although this method is attractive, only a small fraction of selected 
compounds recognize novel binding pockets. Small molecules, often attracted to the active site 
that is rich in functional groups, do not extend into the adjacent binding sites due to their small 
size. In addition, this HTS approach requires a huge investment of time and money, and 
therefore is primarily an enterprise for industry (Hardy and Wells, 2004; Sperandio et al., 
2008).  
In recent years, peptide-based affinity reagents are increasingly used to identify new 
druggable surfaces on targets. Indeed, there are a number of peptide inhibitors that target a 
range of kinases (Bogoyevitch et al., 2005; Eldar-Finkelman and Eisenstein, 2009). A majority 
of these inhibitors are synthetic linear peptides, which are either isolated from a library of 
chemically synthesized peptides or rationally designed to mimic the recognition sequences of 
specific kinase-binding proteins. There are a few recombinant constrained peptides, called 
peptide aptamers, which are isolated from genetically encoded peptide libraries (Kolonin and 
Finley, 1998; Buerger et al., 2003; Kunz et al., 2006; Martel et al., 2006; Miller et al., 2007). In 
many cases, these synthetic or recombinant peptides function as competitive inhibitors by 
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binding to the substrate peptide-binding region of kinases. In a few cases, these peptides inhibit 
protein-protein interactions by targeting the regulatory domains of kinases.   
 To date, there are no peptide inhibitors that target the adenosine triphosphate (ATP) 
binding site of kinases. Small peptides that can function as ATP competitive inhibitors would 
prove useful in identifying and validating new druggable surfaces in the kinase catalytic cleft. 
These peptides, being larger than small molecules, have the potential to target the ATP binding 
pocket as well as surfaces that lie adjacent to this pocket. Such peptides recognizing novel 
binding pockets can be made useful in several ways: (i) structure of the kinase domain in 
complex with the peptide could be solved, which would provide information for the rational 
design of small molecule drugs; (ii) small molecules that disrupt kinase-peptide interactions 
could be identified by performing peptide displacement screens (Bardou et al., 2009), which in 
turn would serve as lead structures for drug development; and (iii) novel pharmacophores of the 
peptide could be grafted onto an existing small molecule using peptidomimetics (Vagner et al., 
2008), to design a next generation drug that recognizes additional binding pockets. 
In this thesis, we describe the isolation and characterization of a novel class of cyclic 
peptides, referred to as lariats, that bind to the catalytic cleft of Abelson (Abl) kinase, a drug 
target important in chronic myeloid leukemia (CML) and other disorders (Advani and 
Pendergast, 2002; Hantschel and Superti-Furga, 2004). 
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2. Literature Review  
2.1 Molecular recognition of protein kinases by small molecules 
2.1.1 Protein kinases as drug targets 
Protein kinases are phosphotransferases, which catalyze the transfer of γ-phosphate 
from ATP to the hydroxyl group of defined tyrosine, serine, and threonine residues in various 
protein substrates. Phosphorylated proteins initiate a cascade of reactions downstream, playing 
essential roles in cell-signaling pathways. As phosphorylation acts as a biological control 
process in modulating a wide range of cellular events, abnormal phosphorylation is often a 
cause or consequence of diseased states (Johnson and Lewis, 2001; Parang and Sun, 2005). The 
human genome encodes 518 putative kinases, of which 164 kinases are implicated in cancer 
and 80 kinases are implicated in other non-malignant disorders, making the kinome a rich 
source of therapeutic targets (Manning et al., 2002; Cohen, 2002; Greenman et al., 2007). Few 
well-studied kinase targets that are intimately involved in cancer are listed in Table 2.1 (Blume-
Jensen and Hunter, 2001; Futreal et al., 2004; Perez-de-Castro et al., 2007; Zhang et al., 2009).  
Kinase targets implicated in cancer are grouped into three classes. The first class 
contains kinases that acquire transforming capacity upon mutation and deregulation (Zhang et 
al., 2009). These kinases are primary targets for cancer intervention (Weinstein et al., 2006). 
Among the primary targets, Abl kinase is a classic example. Abl kinase has been implicated in 
processes of cell division, cell differentiation, actin dynamics, cell migration, and oxidative 
stress and DNA-damage responses (Pendergast, 2002; Smith and Mayer, 2002). Tight temporal 
and spatial control of Abl kinase activity is essential for normal cell function, growth and 
development. Aberrant Abl kinase activity leads to different forms of leukemia in humans 
(Hantschel and Superti-Furga, 2004). In CML and a subset of acute lymphocytic leukemia 
(ALL), a reciprocal translocation between chromosomes 22 and 9 {t(9;22)(q34;q11)}, in which 
sequences of the first exon of ABL1 gene are replaced by sequences from the BCR (Breakpoint 
Cluster Region) gene, results in expression of the Bcr–Abl fusion protein (Daley et al., 1990). 
In the fusion protein, Abl lacks the N-terminal region that carries a myristoyl modification. 
Lacking this modification, Bcr-Abl becomes constitutively active, as the myristoyl group is a 
negative regulator of native Abl kinase activity (Nagar et al., 2003; Hantschel et al., 2003). The 
Bcr coiled-coil domain, located in the N-terminus of the Bcr moiety, also favors constitutive 
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Table 2.1: Examples of protein kinases implicated in human cancer (Table modified with 
permission from Macmillan Publishers Ltd: Nature Reviews in Cancer, (Zhang et al., 2009)). 
Kinase  Oncogenic Alteration Tumor/Cancer Types 
Abl Translocation (BCR-) CML 
Src Overexpression, C-terminal truncation  Lung, colon, breast & 
prostate 
Jak-2 Translocation (TEL-), point mutations CML, T-ALL 
c-Yes, Akt, Aurora, 
Cdks, mTOR, Plk, 
S6K, PKC 
Overexpression Multiple 
ATM Point mutations Ataxia telangiectasia 
b-Raf Point mutations Colon, thyroid, melanoma 
PI3K Overexpression and point mutations  Prostate, colorectal, breast 
SK1 Overexpression Breast 
EGFR Extracellular domain deletions and 
point mutations  
Breast, lung, glioma  
HER-2/ErbB2  Overexpression Breast, ovarian, colon, 
lung, gastric  
IGF-IR  Overexpression Colorectal, pancreatic, 
breast, ovarian 
PDGFR-α  Overexpression and translocation  Glioma, ovarian 
PDGFR-β  Translocation (TEL-) CMML, glioma, DFSP  
c-Kit  Point mutations GIST, seminoma  
Flt-4, Flt3  Internal tandem duplication  AML 
FGFR1  Translocations (BCR-, FOP-, ZNF198-, 
CEP110-) 
Myeloproliferative 
disorders 
FGFR3  Translocations & point mutations  Multiple myeloma  
FGFR4 Overexpression Breast, ovarian  
c-Ret, c-Met, Alk Translocations & point mutations  Multiple 
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activation by inducing dimerisation of the fusion protein (McWhirter et al., 1993; Zhang et al., 
2001). Critical signals emanate downstream of the Bcr-Abl fusion protein and lead to 
oncogenic transformation of haematopoietic stem cells (Samanta et al., 2010) (Figure 2.1).  
A second class of kinase targets is required for sustaining rapid proliferation and/or 
survival of cancer cells. These kinases, however, are not oncogenic and are rarely mutated in 
cancer (Zhang et al., 2009). Examples of this class include (i) mitogen-activated protein kinase 
kinase 1/2 (Mek1/2), ribosomal S6 kinase (Rsk), and mammalian target of rapamycin (mTOR) 
kinase, which are located downstream of transforming oncogenes in signaling pathways (Hu et 
al., 2004; Faivre et al., 2006; Wang et al., 2007); (ii) cyclin-dependent kinases (Cdk) and polo-
like kinases (Plk), which are important regulators of the cell cycle; and (iii) aurora kinases, 
which play a crucial role during mitosis and cytokinesis (Malumbres and Barbacid, 2007). 
A third class of kinase targets is required for different stages of tumor formation. These 
kinases are overexpressed in the tumor or in surrounding tissues (Zhang et al., 2009). Examples 
of this class include (i) vascular endothelial growth factor receptor (VEGFR) and fibroblast 
growth factor receptor (FGFR), which are essential in tumor angiogenesis (Kerbel, 2008); (ii) 
neurotrophic growth factor receptor, which may be required for tumor cell metastasis (Geiger 
and Peeper, 2007); and (iii) M2 splice isoform of pyruvate kinase, which is important for 
cancer metabolism and tumor growth (Christofk et al., 2008).  
Protein kinases are also targets for treatment of non-malignant disorders such as cardiac 
hypertrophy, pulmonary hypertension, lung fibrosis, rheumatoid disorders, atherosclerosis, in-
stent restenosis, glomerulonephritis, cystic fibrosis, asthma, chronic obstructive pulmonary 
disease, gastritis, psoriasis, sepsis, and macular degeneration (Grimminger et al., 2010). 
2.1.2 Protein kinase inhibitors 
On the market in the United States, there are currently 11 FDA approved small 
molecule inhibitors that target a range of kinases (Table 2.2). Nine out of these 11 inhibitors 
target the ATP-binding pocket of kinases, and two molecules inhibit protein-protein 
interactions (Force and Kolaja, 2011). Three ATP competitive inhibitors (imatinib, dasatinib 
and nilotinib) are used to treat leukemias (Wei et al., 2010). Their modes of action are 
discussed in detail later. In addition to the FDA approved drugs, there are many ATP-
competitive and a few allosteric inhibitors in various phases of development and clinical trials. 
	   6	  
	  
Figure 2.1: (a) Primary structure of Abl kinase and its variants: Abl kinase contains SH3, 
SH2, kinase (SH1), DNA binding and actin binding domains. NLS and NES represent nuclear 
localization signal and nuclear export signal, respectively. Abl(1b) but not Abl(1a) is 
myristoylated. Bcr-Abl and v-Abl are two N-terminal mutants of Abl kinase. In the clinically 
important Bcr-Abl fusion protein, Abl lacks the N-terminal region that carries a myristoyl 
modification (Cap sequence). In the Gag-Abl fusion protein, Abl lacks the Cap sequence and 
the SH3 domain. (b) Tertiary structure of Abl SH3-SH2-SH1: Backbone worm 
representation of myristoylated Abl SH3-SH2-SH1 in complex with PD16 inhibitor is shown. 
Dotted line represents the Cap sequence region. Some important residues and secondary 
structure elements are indicated. The myristoyl moiety binds to a hydrophobic pocket in the C- 
lobe of the kinase domain, which is important for establishing the latent conformation of Abl. 
(c) Oncogenic signaling of Bcr-Abl: Bcr-Abl protein expression leads to the activation of 
multiple downstream signalling events such as Ras/Raf/Mek/Erk, Jak2/Stat3b, Hck/Stat5b and 
PI3K/PTEN/Akt/mTOR pathways, which contribute to growth and survival. Figure 2.1(a) 
reprinted with permission from Macmillan Publishers Ltd: Nature Cell Biology, (Wang, 2004).  
Figure 2.1(b) reprinted with permission from Elsevier: Cell, (Hantschel et al., 2003). 
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Table 2.2: Eleven FDA approved protein kinase inhibitors and their targets (Table 
modified with permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery, 
(Force and Kolaja, 2011)). 
Drug Brand 
name 
Company Launc-
-hed in 
Primary target(s) Disease 
Imatinib  Gleevec Novartis 2001 Abl, PDGFR, c-Kit CML etc., 
Gefitinib  Iressa AstraZeneca 2003 EGFR NSCLC 
Erlotinib  Tarceva Roche/Genentech 2004 EGFR NSCLC, 
PC etc., 
Sorafenib  Nexavar Bayer 2005 B-Raf, VEGFR, 
PDGFR, Flt3, c-Kit 
RCC, LC 
Sunitinib  Sutent Pfizer 2006 VEGFR, PDGFR, 
CSF1R, Flt3, c-Kit 
RCC, 
GIST 
Dasatinib  Sprycel Bristol-Myers 
Squibb 
2006 Abl, c-Kit, PDGFR, 
Src 
CML 
Temsirolimus  Torisel Pfizer 2007 mTOR RCC 
Nilotinib  Tasigna Novartis 2007 Abl, PDGFR, c-Kit CML 
Lapatinib  Tykerb GlaxoSmithKline 2007 EGFR  BC 
Everolimus  Afinitor Novartis 2009 mTOR RCC 
Pazopanib  Votrient GlaxoSmithKline 2009 VEGFR, PDGFR,  
c-Kit 
RCC 
 
Allosteric inhibitors bind outside the ATP-binding pocket and modulate the kinase 
activity in an allosteric manner. Well-studied allosteric inhibitors include: (i) GNF2 and GNF5, 
which bind to the myristate-binding pocket of Abl kinase (Adrian et al., 2006; Zhang et al., 
2010) (ii) ON012380 and ON44580, which bind to the substrate-binding pocket of Abl kinase 
and Janus kinase 2 (Jak2), respectively (Gumireddy et al., 2005; Jatiani et al., 2010) (iii) 
PD318088, which inhibits Mek1/2 by occupying an allosteric site adjacent to the ATP binding 
pocket (Ohren et al., 2004); (iv) protein kinase B inhibitors, which target the pleckstrin 
homology domain (Lindsley et al., 2005); and (v) BMS-345541, which inhibits nuclear factor-
κB kinase by binding to an allosteric site on the enzyme (McIntyre et al., 2003).  
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Apart from the inhibitors mentioned here, there are also: (i) covalent inhibitors, which 
are capable of forming an irreversible, covalent bond to the kinase active site (Cohen et al., 
2005; Kwak et al., 2005); (ii) bisubstrate analog inhibitors, which are designed to mimic two 
natural ligands that simultaneously associate with ATP and peptide binding sites of kinases 
(Parang and Cole, 2002); (iii) SH2 domain inhibitors, which antagonize SH2 domain dependent 
protein-protein interactions (Vu, 2000; Muller, 2000; Wojcik et al., 2010); and (iv) humanized 
monoclonal antibodies, which are generated against growth factors and their receptors [e.g. 
bevacizumab that targets vascular endothelial growth factor for treatment of metastatic 
colorectal cancer (Fuh et al., 2006), and trastuzumab that targets the exracellular domain of 
epidermal growth factor receptor 2 (HER-2/ErbB2) for treatment of breast cancer (Cho et al., 
2003)].  
2.1.3 Structural features of the catalytic domain of kinases  
All kinases have a conserved catalytic domain consisting of ~ 300 residues (Johnson, 
2009). In addition to the catalytic domain, kinases contain several other domains. However, 
only the catalytic domain structure is discussed here, since all the kinase inhibitors used in the 
clinic bind to this domain. The catalytic domain of kinases folds into two lobes, a smaller N-
terminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe) (Figure 2.2). The two lobes are 
connected with a linker that contains a hinge and a convex shaped motif (E0). The active site is 
present in the interlobal cleft (Liao, 2007a). The N-lobe consists of five β strands (β1 – β5), and 
one α helix (αC). The glycine-rich loop (G-loop), between β1 and β2, is an important structural 
element in the N-lobe (Hubbard and Till, 2000; Huse and Kuriyan, 2002). The C-lobe is mainly 
α helical and contains only four short β strands (β6 – β9). This stable helical subdomain serves 
as a tethering surface for protein/peptide substrates, and also houses a myristic acid binding 
pocket.  Important structural elements in the C-lobe include a catalytic loop, an activation 
segment (A-segment) and one α helix (αF). The catalytic loop is present between β6 and β7 and 
has most of the catalytic machinery. The A-segment consists of DFG motif, β9, activation loop 
(A-loop), and P + 1 loop (Huse and Kuriyan, 2002; Nolen et al., 2004). The hydrophobic F 
helix is the organizing element for the entire kinase core. Motifs in the C-lobe are anchored 
firmly through hydrophobic contacts to the F- helix (Taylor and Kornev, 2011). 
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Figure 2.2. Conserved structure of kinase catalytic domain: Ribbon representation of kinase 
core in complex with ATP is shown. Important secondary structure elements are indicated. See 
section 2.1.3 for details. Figure reprinted with permission from Elsevier: Trends in Biochemical 
Sciences, (Taylor and Kornev, 2011). 
2.1.4 Structure and activation of the kinase catalytic cleft 
The catalytic cleft is formed between the N- and C- lobes (Figure 2.3). The basic 
structural features of the cleft include nine β strands (β1-β5 in the N-lobe and β6-β9 in the C-
lobe), two α helices (αC in the N-lobe and αE in the C-lobe), two loops (G-loop and the 
catalytic loop), and the A-segment. Five β strands (β1-β5) and the G-loop form the ceiling of 
the cleft. The C-terminus of αE, N-terminus of the catalytic loop, β7, β8 and the DFG motif 
constitute the basement of the cleft (Liao, 2007a; Liao and Andrews, 2007).  
The catalytic cleft is composed of two regions: (i) the front cleft that contains 
predominantly the ATP-binding site; and (ii) the back cleft that contains elements important for 
regulation of kinase catalysis. The two regions are bordered by β3, β8 and the DFG motif. Two 
residues (K271 in β3 and T315 in β5) form an internal gate between the front and the back 
clefts (Huse and Kuriyan, 2002; Nolen et al., 2004). Here, the crystal structure of active Abl 
kinase is used for discussion.  The T315 residue is referred to as the gatekeeper. The gatekeeper 
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Figure 2.3. Basic structural features of the kinase catalytic cleft: Ribbon representation of 
Abl kinase catalytic cleft (PDB code: 2G2I) in active conformation is shown. Important 
residues and secondary structure elements are indicated. See section 2.1.4 for details. Figure 
reprinted with permission from Bentham Science Publishers Ltd: Current Topics in Medicinal 
Chemistry, (Liao and Andrews, 2007). 
residue controls the access to the back cleft. A small amino acid (threonine or alanine) at this 
position allows access to the back cleft, while a bulky gatekeeper (phenylalanine, leucine or 
methionine) blocks the access to the back cleft (Liu et al., 1998; Bishop, 2004). Another 
component of the gate, the β3 lysine, also plays an important role in the catalysis. The lysine 
couples the non-transferable α and β phosphates of the ATP to the helix αC by forming an ion 
pair with the catalytic glutamate residue (E286 in Abl) located nearly at the centre of αC. The 
lysine–glutamate salt bridge is highly conserved through the entire kinase family (Hanks and 
Hunter, 1995; Wu et al., 2003). 
Depending on the conformational state of the kinase and the presence of a ligand, the G-
loop, the A-segment, and the αC helix can adopt various conformations. In the fully active state 
(Figure 2.4), the A-segment adopts an open conformation and provides a platform for substrate 
binding. The A-segment in the open conformation is also called the DFG-in conformation, 
where the side chain of D381 in the DFG motif is directed into the ATP binding site, and the 
aromatic ring of F382 is positioned in the back cleft. In the DFG-in state, D381 chelates Mg2+ 
that orients the γ-phosphate of ATP for transfer, and the aromatic ring of F382 contacts the αC 
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helix to promote αC-in conformation. The αC-in conformation, characterized by an inward shift 
of the αC helix with its E286 pointing towards the cleft, facilitates the formation of the lysine–
glutamate salt bridge mentioned earlier. Overall, an active kinase requires the DFG-in and the 
αC-in conformations for catalysis. For a stable active kinase conformation, phosphorylation of 
a critical residue in the A-segment by an upstream kinase is required (Huse and Kuriyan, 2002; 
Nolen et al., 2004, Levinson et al., 2006).   
The inactive kinases are characterized by DFG-out and/or αC-out conformations. In the 
DFG-out state, the A-segment adopts a closed conformation and interferes with substrate 
binding. The aromatic ring of F382 is positioned in the ATP binding site and the side chain of 
D381 occupies the back cleft. In the αC-out state, there is an outward shift of the αC helix, 
which makes E286 point out of the catalytic cleft (Huse and Kuriyan, 2002; Nolen et al., 2004, 
Levinson et al., 2006). Two different inactive conformations of Abl kinase (Abl/c-Kit–like 
inactive state [DFG-out, αC-in] and Src/Cdk–like inactive state [DFG-in, αC-out]) are shown in 
Figure 2.4. 
 
Figure 2.4. Multiple states of Abl kinase: Ribbon representations of three key Abl catalytic 
domain conformations are shown. (a) Abl/c-Kit–like inactive conformation (DFG-out, αC-in); 
(b) Src/Cdk–like inactive conformation (DFG-in, αC-out); and (c) active conformation (DFG-
in, αC-in). Src/Cdk–like inactive state is one of the intermediate conformations adopted by Abl 
kinase during the activation process. Important residues and secondary structure elements are 
indicated in the figure. PDB codes: 1OPJ (for A), 2G1T (for B), and 2G2I (for C). Figure 
reprinted from PLOS Biology (Levinson et al., 2006) under Creative Commons Attribution 
License.
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2.1.5 Binding pockets in the catalytic cleft 
Though the following section is based mainly upon published articles (Noble et al., 
2004; Liu and Gray, 2006; Liao, 2007a; Liao, 2007b; Liao and Andrews, 2007; Johnson, 2009), 
personal observations gained from detailed structure, sequence and binding-site analyses are 
also incorporated. Human Abl 1b numbering is used throughout the discussion. The front cleft 
contains four binding pockets (denoted A, R, P and K pockets) and two entrance regions 
(denoted E0 and E1). The hydrophobic adenine-binding pocket (A-pocket) provides a major 
scaffold for ATP/inhibitor binding. This pocket is covered by five hydrophobic residues (L248 
in β1, V256 in β2, A269 in β3, V299 in the loop between αC and β4, and L370 in β6) and 
rimmed with gatekeeper (T315 in β5) and hinge residues (E316, F317, and M318 in the loop 
between β5 and αD). The first and the third hinge residues form hydrogen bonds (H-bond) with 
adenine (Brown et al., 1999) or ATP competitive small molecules (Cherry et al., 2004). 
Although the A-pocket is highly conserved in the kinase family, the gatekeeper and a few other 
residues have specific features in this pocket, which are used to gain selectivity in the design of 
inhibitors. For example, the smaller alanine (A269 in Abl) conserved in many kinases 
(Manning et al., 2002) is replaced by a bulkier residue (V66) in casein kinase II. In addition, 
the entrance region E0 lining the A-pocket varies in sequence and conformation, thereby 
providing opportunities for selective drug design (Fabbro et al., 2002). This E0 region often 
serves as an entrance for the binding of ATP competitive small molecules. 
The ribose-binding pocket (R pocket) is covered by three hydrophobic residues (L248, 
V256, and L370 (shared with the A-pocket)), first two residues (backbone) in the G-loop (G249 
and G250), two residues in the loop between β5 and αD (G321 and N322), D325 in αD, and 
R367 in the catalytic loop. The entrance region E1 that lies adjacent to the R-pocket is 
hydrophilic and solvent-exposed. The triphosphate-binding pocket (P pocket) is lined with the 
G-loop from the top, three residues in the catalytic loop (D363, A365 and N368), K271 in β3, 
and D381 in the DFG motif. The P pocket is highly flexible, hydrophilic and solvent-exposed. 
Therefore, this pocket is believed to be less important for improving the affinity of the inhibitor 
(Fabbro et al., 2002). However, the P pocket could be utilized to improve the selectivity and 
physicochemical properties of the inhibitor (Kontopidis et al., 2006). With the exception of few 
highly selective inhibitors, the majority of ATP competitive small molecules do not exploit the 
R and P pockets (Zhang et al., 2009). The K pocket, a relatively small, non-ATP contact region 
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is located in the deep front pocket and is covered by four residues (K271, T315, A380, and 
D381). 
Two binding pockets (denoted BPI and BPII) have been identified in the back cleft of 
kinases in the active conformation. Upon adopting the inactive conformation (DFG-out), the 
back cleft of kinases is enlarged and therefore four binding sites (denoted BPI – BPIV) have 
been identified. Residues that cover the binding pockets in the back cleft of Abl kinase are 
given in Table 2.3. Topological distribution of the binding pockets in the catalytic cleft with 
active (DFG-in, αC-in) and inactive (DFG-out, αC-in) conformations is shown in Figure 2.5. In 
order to achieve high selectivity and affinity, inhibitors are rationally designed to target many 
binding sites in the front and the back clefts of kinases.   
2.1.6 Binding modes of kinase inhibitors 
Based on the mode of binding, the inhibitors that bind within the catalytic cleft are 
classified into three types: type I, type II, and allosteric kinase inhibitors. Type I and type II 
kinase inhibitors are ATP competitive and bind predominantly to the A-pocket. Typically, all 
type I/II inhibitors form one to three H-bonds with the hinge residues. Allosteric inhibitors 
(type III) bind outside the ATP binding pocket and are non-ATP competitive (Okram et al., 
2006; Liu and Gray, 2006; Zhang et al., 2009). 
 
	  
Figure 2.5. Topological distribution of binding pockets in the kinase catalytic cleft: (a) 
with active (DFG-in, αC-in); and (b) with inactive (DFG-out, αC-in) conformations. Adenine 
(A), ribose (R), phosphate (P), and K pockets are located in the front catalytic cleft. Binding 
pockets I, II (DFG-in or DFG-out), III, and IV are located in the back catalytic cleft. E0, E1, and 
E2 denote various entrance regions that surround the cleft. Figure reprinted with permission 
from Bentham Science Publishers Ltd: Current Topics in Medicinal Chemistry, (Liao, 2007b).
	   14	  
Table 2.3: Residues lining the binding pockets located in the back cleft of Abl kinase  
Pocket Cleft conformation Residues 
BPI Active  
(DFG-in, αC-in) 
Inactive  
(DFG-in, αC-out) 
(DFG-out, αC-in) 
A269 (in β3) 
K271 (catalytic lysine in β3) 
M290 (in αC) 
I313, I314 (in β5) 
T315 (gatekeeper in β5) 
BPII Active 
(DFG-in, αC-in) 
E286 (catalytic Glutamate in αC) 
M290 (in αC) 
V299, E300, L301 (in loop between αC and β4) 
T315 (gatekeeper in β5) 
A380 (in β8) 
D381, F382, G383 (DFG motif in activation loop) 
BPII Inactive 
(DFG-in, αC-out)   
M290 (in αC) 
V299, E300, L301 (in loop between αC and β4) 
T315 (gatekeeper in β5) 
A380 (in β8) 
D381, F382, G383 (DFG motif in activation loop) 
BPIII Inactive 
(DFG-out, αC-in)	   V289 (in αC)  I293, L298 (in loop between αC and β4) 
L354 (in αE) 
H361 (in catalytic loop) 
A380 (in β7) 
BPIV Inactive 
(DFG-out, αC-in)	   V289 (in αC)  L354 (in αE) 
F359, I360, H361 (in catalytic loop) 
D381 (in DFG motif) 
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Type I inhibitors can bind to kinases in both the active and inactive conformations, but 
so far all type I inhibitors have been co-crystallized with kinases in the active conformation. 
Examples of this class include dasatinib, erlotinib, sunitinib, and VX-680. In addition to the A-
pocket, type I inhibitors can also occupy R, P, BPI, and BPII pockets. Type II inhibitors require 
a specific inactive conformation of the kinase for binding. Examples of this class include 
imatinib, nilotinib, lapatanib, and sorafenib. In addition to the A-pocket, type II inhibitors can 
also occupy R, P, BPI, BPII, BPIII, and BPIV pockets (Liu and Gray, 2006; Liao, 2007a; Liao 
and Andrews, 2007; Johnson, 2009; Zhang et al., 2009). Specific conformations of the 
activation loop and the αC helix targeted by these inhibitors are given in Table 2.4. 
Allosteric inhibitors that bind within the catalytic cleft target a region adjacent to the 
ATP binding site. They exploit very specific and unique binding sites in the back cleft. 
Examples of this class include Mek1/2 inhibitor PD318088 (Ohren et al., 2004) and its 
derivatives PD184352 and PD325901. PD318088 recognizes two binding pockets in the Mek1 
back cleft (BPII and BPIIII) but does not bind to the A, R, and P pockets in the front cleft (Liao, 
2007a). BPIIII is a new hydrophobic half-opened binding pocket, which is different from the 
BPIII pocket. PD318088 binds to the target through the E2 entrance at the αC side. Binding 
modes of type I, type II and allosteric inhibitors are illustrated in Figure 2.6.  
Table 2.4: Conformational preferences for the binding of kinase inhibitors 
Targeted Conformation Inhibitor Type 
Catalytic cleft Activation loop αC helix 
Dasatinib I Active DFG-in αC-in 
VX-680 I Active	   DFG-in αC-in 
Erlotinib I Active	   DFG-in αC-in 
Sunitinib I Active	   DFG-in αC-in 
Imatinib II Inactive DFG-out αC-in 
Nilotinib II	   Inactive	   DFG-out αC-in 
Lapatanib II	   Inactive	   DFG-in αC-out 
Sorafenib II	   Inactive	   DFG-out αC-in 
PD318088 III Inactive	   DFG-out αC-out 
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Figure 2.6. Binding modes of kinase inhibitors in the catalytic cleft: Type I inhibitors - (a) 
dasatinib in active Abl; (b) VX-680 in active Abl; (c) erlotinib in active EGFR; and (d) 
sunitinib in active FGFR. Type II inhibitors - (e) imatinib in inactive Abl; (f) nilotinib in 
inactive Abl; (g) lapatinib in inactive EGFR; and (h) sorafenib in inactive B-Raf. Type III 
inhibitor – (i) PD318088 in inactive Mek1. ATP binding is shown in (i) for reference.  Adenine 
(A), ribose (R), phosphate (P), and K pockets are located in the front catalytic cleft. Binding 
pockets I, II, III, IIII, and IV are located in the back catalytic cleft. E0, E1, E2, and E2 denote 
various entrance regions that surround the cleft. Figures 2.6 (a-e) and (g-i) reprinted with 
permission from American Chemical Society: Journal of Medicinal Chemistry, (Liao, 2007a). 
Figure 2.6 (f) reprinted with permission from Bentham Science Publishers Ltd: Current Topics 
in Medicinal Chemistry, (Liao and Andrews, 2007). 
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2.1.7 Selectivity and resistance profiles of kinase inhibitors 
In order to minimize the side effects of kinase inhibitors in patients, selective inhibition 
of only a few kinases is essential. Type I, type II and allosteric inhibitors have varying degrees 
of selectivity (Karaman et al., 2008). As the catalytic cleft of all kinases exhibit a similar 
conformation in the active state (Figure 2.7a), inhibitors that target the active form of kinases 
(type I) exhibit poor kinase selectivity. In contrast, inhibitors that target the specific inactive 
conformation of kinase (type II) achieve a high degree of selectivity relative to type I inhibitors. 
This is because structures of inactive forms of kinases are much more varied and specific for a 
particular kinase (Figure 2.7b) (Liu and Gray, 2006; Johnson, 2009). For example, imatinib 
recognizes a specific Abl/c-Kit like inactive conformation in Abl kinase and does not bind to 
Src kinase, which adopts a different Src/Cdk like inactive conformation. Abl and Src kinases 
look very similar in their active state and therefore dasatinib, a type I inhibitor binds to both 
kinases. Allosteric or type III inhibitors exhibit the highest degree of selectivity because they 
bind outside the conserved A-pocket and recognize unique binding pockets in the back cleft 
(Zhang et al., 2009). 
	  	  	  	  	  	   	  
Figure 2.7. Conformation of the activation segment in different kinases present in active 
and inactive states: (a) Since there is a need for catalysis, activation segments of kinases have 
a highly conserved conformation in their active state; and (b) Geometry of the activation 
segment changes significantly and is not structurally conserved upon inactivation. Figure 
reprinted with permission from Elsevier: Trends in Biochemical Sciences, (Taylor and Kornev, 
2011). 
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In addition to selectivity, drug-resistant mutations in patients have become a significant 
issue in kinase-targeted anticancer therapy. A number of resistant mutations have been detected 
in the catalytic and regulatory domains of kinases. The majority of the resistant mutations can 
be grouped into two classes: (i) mutations within the catalytic cleft, which directly impair drug 
binding by loss of bonded/steric interactions; and (ii) allosteric drug-resistant mutations, which 
indirectly impair drug binding by shifting the conformation of the kinase towards the active 
form. Allosteric drug-resistant mutations emerge as a result of targeting a specific inactive 
conformation of the kinase, which imposes a strong selective pressure for cells to acquire 
mutations that activate kinases and impair drug binding (Krishnamurthy and Maly, 2010).  
Comprehensive analysis of the selectivity and resistance profiles of kinase inhibitors 
has revealed that the two different profiles are related to one another (Figure 2.8). As shown in 
the case of Abl kinase (Figure 2.4), kinases can adopt multiple conformations. The specificity 
of these structures is increased from the active to the inactive conformation. Therefore, type II 
inhibitors targeting a specific inactive conformation of the kinase have narrow selectivity 
profiles. However, these inhibitors are affected by a large number of allosteric activating 
mutations leading to broad resistant mutation profiles. On the other hand, type I inhibitors 
targeting less specific (active) or multiple conformations of the kinase possess broad selectivity 
and narrow resistant mutation profiles (Liao, 2007b).  
2.2. Lariat peptide technology 
In order to perform reverse analysis with cyclic peptides using genetic assays, we 
developed a new technology (Barreto et al., 2009) that generates lariat cyclic peptides against 
any protein of interest. Lariat peptides are lactone-cyclized peptides, which consist of a “noose” 
region with a covalently attached transcription activation domain. Lariats with known 
sequences or lariat peptide libraries are generated by engineering specific mutations to the 
intein cyclic peptide producing system (Scott et al., 1999), which halts the cyclic peptide 
reaction at an intermediate step and produces a lariat (Figure 2.9). The transcription activation 
domain is incorporated into the lariat in order to facilitate the screening of a combinatorial 
lariat peptide library against a known target using the yeast two-hybrid (Y2H) interaction trap 
(Figure 2.10). Using this technology, we have isolated lariats against different classes of 
proteins and characterized them in vitro and in vivo.  
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Figure 2.8. Selectivity and resistant mutation profiles of a kinase inhibitor are correlated 
with each other: (a) kinome interaction map for imatinib, a type II inhibitor; (b) kinome 
interaction map for dasatinib, a type I inhibitor; and (c) resistant mutation profiles of imatinib 
and dasatinib.  Type II inhibitors have narrow selectivity and broad resistant mutation profiles. 
Type I inhibitors have broad selectivity and narrow resistant mutation profiles. Figures 2.8(a) 
and 2.8(b) reprinted with permission from Macmillan Publishers Ltd: Nature Biotechnology, 
(Karaman et al., 2008). Table (2.8c) modified and redrawn from O’Hare et al., 2005. 
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Figure 2.9. Schematic of intein processing: (a) Intein mediated cyclic peptide production: 
Inteins are naturally occurring proteins, which catalyze a self-splicing reaction by removing 
themselves from the precursor protein. This reaction results in the ligation of exteins and 
produces the mature protein. In order to catalyze a cyclization reaction using inteins, the order 
of the intein domains are permutated by protein engineering (IN-extein-IC to IC-extein-IN), 
which enables the head to tail cyclization of the extein. IN and IC represent N-terminal and C-
terminal domains of intein. The cyclization reaction proceeds in four steps: (i) Unprocessed 
intein undergoes an N-to-S acyl shift using the IN+1 Cys at the peptide-IN junction; (ii) 
Transesterification reaction involving IC+1 Ser at the IC-peptide junction and the thioester 
formed in step (i), which releases the IN domain and produces the lariat intermediate; (iii) IC-1 
Asn undergoes a side chain cyclization, which releases the IC domain and generates a lactone-
cyclized peptide; and (iv) Lactone-cyclized peptide undergoes a thermodynamically favored O-
to-N acyl shift to produce a lactam-cyclized peptide. (b) Intein mediated lariat peptide 
production: Lariat peptides are produced by mutating the Asn at position IC-1 to Ala (*), which 
inhibits asparagine cyclization and stops the reaction at the lariat intermediate. The lariat is 
useful for applications such as yeast two-hybrid screening, allowing a transcription activation 
domain to be attached to the N-terminus of the lariat (IC domain). In this way libraries of 
genetically encoded cyclic peptides can be screened for an interaction with a target protein. X7-
EY represents the peptide “noose” region, which codes for a seven random amino acids, 
followed by Glu and Tyr. Figure reprinted with permission from Elsevier: Chemistry and 
Biology, (Barreto et al., 2009). 
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Figure 2.10. Lariat yeast two-hybrid interaction trap: The LexA operator (LexAop) is 
upstream of stably integrated LEU2, ADE2, and LacZ reporter genes. Plasmid pEG202 
expresses LexA-target protein fusion, which binds to the LexA operator. Plasmid pIN01 
expresses members of the lariat library that contain the peptide “noose” region and the IC 
domain fused to an N terminus haemagglutinin (HA) tag, a transcription activation domain 
(ACT), and a nuclear localization sequence (NLS). Lariats that interact with the target protein 
bring the transcription activation domain near the transcription start sites of the reporter genes 
and activate transcription. The identity of the interacting lariat is determined by sequencing the 
genetic material that encodes the lariat (Figure modified from Barreto, 2010). 
In addition to the validation of new druggable surfaces on the targets, the lariat peptide 
technology can serve many purposes and has multiple advantages: (i) Lariats inhibit their 
protein targets directly and function as trans dominant inhibitors. They block specific 
interactions with a protein while leaving other interactions unperturbed. This is in contrast to 
other reagents like antisense RNA/DNA, ribozymes, and RNAi that block transcription and 
translation of their target; (ii) Lariats are easily and rapidly generated against any target in a 
cost effective manner. Thus, they are easier to generate than small molecules or antibodies; (iii) 
Lariats are constrained by a lactone bond, allowing them to be used in reducing intracellular 
environments. This is in contrast to disulfide bond-constrained peptides, which are not stable 
under reducing conditions and must be screened using in vitro selection strategies such as 
phage display; (iv) Lariats are amenable to chemical synthesis and synthetic lariats are well 
suited for biophysical and structural studies. This is in contrast to peptide aptamers that cannot 
be chemically synthesized but are only over-expressed and purified; (v) The transcription 
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activation domain of lariats can be replaced by other chemical moieties such as affinity tags, 
fluorescent molecules, localization sequences, membrane permeable peptides, etc., which give 
them advantages over ‘‘head-to-tail’’ cyclized peptides that have no free end to attach moieties. 
Together, these properties make lariats ideal reagents for performing forward and reverse 
analysis of cellular processes or protein function (Barreto et al., 2009). 
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3. Objective and Specific Aims 
A number of drug discovery programs have demonstrated that the ATP binding pocket 
of kinases are remarkably adaptable for the design of inhibitors. Despite the substantial 
achievements in this field, design of novel inhibitors with high degrees of specificity remains a 
major challenge. As the vast majority of inhibitors predominantly occupy the highly conserved 
adenine-binding pocket, it becomes essential to exploit the less conserved adjacent pockets, in 
order to design highly specific next-generation drugs. Lariat peptides, 7-10 amino acids in 
length, provide an avenue to identify and validate new druggable surfaces located in the kinase 
catalytic cleft, as they are larger than small molecule drugs. This additional size provides added 
functionality that could be used to bind the ATP binding pocket as well as surfaces adjacent to 
this pocket. Further, lariats have the potential to easily generate useful structure-activity 
relationship data for rational drug design, in a rapid and cost-effective manner. Taking 
advantage of our established lariat peptide technology, the objective of this thesis is to isolate 
and characterize ATP competitive lariats of Abl kinase, a drug target important in chronic 
myelogenous leukemia and other disorders. To achieve this objective, the following aims were 
devised. 
Specific Aim 1: Isolate lariat peptide inhibitors of Abl SH1 from the combinatorial Ssp-Ssp R7 
lariat library and characterize their mechanism of action. 
Specific Aim 2: Delineate important residues of the lariat and generate tighter-binding variants 
of the lariat. 
Specific Aim 3: Characterize the activity of Abl SH1-interacting lariats in vitro and in vivo, 
and evaluate their selectivity and resistant mutation profiles. 
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4. Materials and Methods 
4.1 General Information 
4.1.1 Strains 
Table 4.1: E. coli strains and genotypes 
Strain Genotype Source/Reference 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac (F ́ proAB lacIqZΔM15 Tn10 (Tetr)) 
Stratagene 
MC1061 F– araD139 Δ(araA-leu)7697 galE15 galK16 
Δ(lac)X74 rpsL (Strr) hsdR2 (rK-mK+) mcrA 
mcrB1 
Wertman et al., 1986 
ER2925 ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 
galK2 galT22 mcrA dcm-6 hisG4 rfbD1 
R(zgb210::Tn10)TetS endA1 rpsL136 
dam13::Tn9 xylA-5 mtl-1 thi-1 mcrB1 hsdR2 
New England Biolabs 
BL21 (DE3) F– ompT gal dcm lon hsdSB (rB- mB-) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5])  
Novagen 
 
Table 4.2: S. cerevisiae strains and genotypes 
Strain Genotype Reference 
EY93 MATa ura2 his3 trp1 leu2 ade2::URA3 Barreto et al., 2009 
EY111 MATα his3 trp1 ura3::LexA8op-LacZ 
ade2::URA3-LexA8op-ADE2 
leu2::LexA6op-LEU2 
Barreto et al., 2009 
 
4.1.2 Antibodies 
Table 4.3: Primary and secondary antibodies and their suppliers 
Antibody Supplier 
Mouse Anti HA antibody Santa Cruz Biotechnology Inc. 
Rabbit Anti FLAG antibody Sigma-Aldrich 
Rabbit Anti Hck antibody Santa Cruz Biotechnology Inc. 
Rabbit Anti p-Hck (Y411) antibody Santa Cruz Biotechnology Inc. 
Rabbit Anti c-Abl antibody Cell Signaling Technology 
Rabbit Anti p-c-Abl (Y412) antibody Cell Signaling Technology 
Goat Anti-Mouse LI-COR IR dye 
(680 and 800CW)  
LI-COR Biosciences 
Goat Anti-Rabbit LI-COR IR dye 
(680 and 800CW) 
LI-COR Biosciences 
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4.1.3 Synthetic Peptides 
Linear and lariat peptides were synthesized by Genscript and Peptide Protein Research, 
respectively. Linear peptides were acetylated at their N-terminus and amidated at their C-
terminus. Lariat versions were created by cyclizing the side chain of serine and the C-terminal 
carboxylic acid via an ester bond. Lariat peptides were acetylated at their N-terminus. 
Sequences of the synthetic peptides can be found in sections 5.1.3 and 5.3.2. 
4.1.4 Oligonucleotides 
Oligonucleotides were synthesized by Integrated DNA Technologies. Their sequences 
in 5’ to 3’ orientation are given in the following table. Serial numbers are used to reference the 
oligonucleotides in the text. P1, P2, Seq and Temp represent forward primer, reverse primer, 
sequencing primer and template, respectively. Oligonucleotides are represented by one letter 
nucleotide codes, where N = (A, C, T, G) and K = (G, T).   
Table 4.4: Oligonucleotide sequences 
S.No Name Sequence 
1 pEG202 Seq P1 GGG CTG GCG GTT GGG GTT ATT C 
2 pEG202 Seq P2 CAT GCC GGT AGA GGT GTG GTC AA 
3 pJG4-5 Seq P1 GGA CAG GAG ATG CCG ATG GA 
4 pJG4-5 Seq P2 GCA AGG TAG ACA AGC CGA CAA C 
5 Inactive A1 Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT GAA TAC GCT TTG TCT TTC GGT ACT 
6 Inactive A2 Temp ATT GCT CAC GCT TCT GGG TGG CAT CGT CTT 
AGT GAG GAA TAC GCT TTG TCT TTC GGT ACT 
7 Linear A1 Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT GAA TAC TAA CTC GAG AAG CTT TGG 
8 Linear A2 Temp ATT GCT CAC GCT TCT GGG TGG CAT CGT CTT 
AGT GAG GAA TAC TAA CTC GAG AAG CTT TGG 
9 Ssp-IC Ins Amp P1 GAT ATT GGT TTG CCA CAA GAT CAC AAC TTC 
TTG TTG GCT AAC GGT GCT ATT GCT CAC GCT 
10 Ssp-IN Ins Amp P2 ATC TTA CCA ATT GGC AAT GGA CCG TAT TCA 
ACA GTC AAA ATT TCA GTA CCG AAA GAC AA 
11 Linear Ins Amp P2 CAA CCT TGA TTG GAG ACT TGA CCA AAC CTC 
TGG CGA AGA AGT CCA AAG CTT CTC GAG TTA 
12 Lariat A1 Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
13 A1/G1 Random Temp ATT GCT CAC GCT TCT NNK TGG CAG CGG CTG 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
14 A1/W2 Random Temp ATT GCT CAC GCT TCT GGT NNK CAG CGG CTG 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
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15 A1/Q3 Random Temp ATT GCT CAC GCT TCT GGT TGG NNK CGG CTG 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
16 A1/R4 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG NNK CTG 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
17 A1/L5 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG NNK 
CCT TTT GAA TAC TGT TTG TCT TTC GGT ACT 
18 A1/P6 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
NNK TTT GAA TAC TGT TTG TCT TTC GGT ACT 
19 A1/F7 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT NNK GAA TAC TGT TTG TCT TTC GGT ACT 
20 A1/E8 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT NNK TAC TGT TTG TCT TTC GGT ACT 
21 A1/Y9 Random Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT GAA NNK TGT TTG TCT TTC GGT ACT 
22 Ssp-IC Ins Amp New P1 ATT GGT TTG CCA CAA GAT CAC AAC TTC TTG 
TTG GCT AAC GGT GCT ATT GCT CAC GCT TCT 
23 Ssp-IN Lar Ins Amp P2 CTT ACC AAT TGG CAA TGG ACC GTA TTC AAC 
AGT CAA AAT TTC AGT ACC GAA AGA CAA ACA 
24 TG1 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TTT GAA TAC TGC TTG TCT TTC GGT ACT  
25 TG2 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
CCT TGG GAA TAC TGC TTG TCT TTC GGT ACT  
26 TG3 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
CCT TAT GAA TAC TGC TTG TCT TTC GGT ACT  
27 TG4 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
CCT TTT AAT TAC TGC TTG TCT TTC GGT ACT  
28 TG5 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
GAT TGG GAA TAC TGC TTG TCT TTC GGT ACT  
29 TG6 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
GAT TAT GAA TAC TGC TTG TCT TTC GGT ACT  
30 TG7 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
GAT TTT AAT TAC TGC TTG TCT TTC GGT ACT  
31 TG8 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TGG AAT TAC TGC TTG TCT TTC GGT ACT  
32 TG9 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TAT AAT TAC TGC TTG TCT TTC GGT ACT  
33 TG10 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TGG GAA TAC TGC TTG TCT TTC GGT ACT  
34 TG11 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TAT GAA TAC TGC TTG TCT TTC GGT ACT  
35 TG12 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TTT AAT TAC TGC TTG TCT TTC GGT ACT  
36 TG13 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
GAT TGG AAT TAC TGC TTG TCT TTC GGT ACT  
37 TG14 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
GAT TAT AAT TAC TGC TTG TCT TTC GGT ACT  
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38 TG15 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
CCT TGG AAT TAC TGC TTG TCT TTC GGT ACT  
39 TG16 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
CCT TAT AAT TAC TGC TTG TCT TTC GGT ACT  
40 TG17 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TGG AAT TAC TGC TTG TCT TTC GGT ACT  
41 TG18 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TAT AAT TAC TGC TTG TCT TTC GGT ACT  
42 ∆E8 A1 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG CGG CTG 
CCT TTT TAC TGC TTG TCT TTC GGT ACT  
43 ∆N8 TG17 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TGG TAC TGC TTG TCT TTC GGT ACT  
44 ∆N8 TG18 Lariat Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TAT TAC TGC TTG TCT TTC GGT ACT  
45 Inactive TG17 Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TGG AAT TAC GCT TTG TCT TTC GGT ACT 
46 Inactive TG18 Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TAT AAT TAC GCT TTG TCT TTC GGT ACT 
47 Linear TG17 Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TGG AAT TAC TAA CTC GAG AAG CTT TGG 
48 Linear TG18 Temp ATT GCT CAC GCT TCT GGT TGG CAG ACG CTG 
GAT TAT AAT TAC TAA CTC GAG AAG CTT TGG 
49 pMSCV Ssp-IC P1 GG GAATTC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT ATG GTT AAG GTT ATT GGT AGA  
50 pMSCV Ssp-IN P2 GG CTCGAG TTA CTT ATC ATC ATC ATC CTT 
GTA ATC CTT AAT AGT ACC AGC ATC CAA CAA  
51 pMSCV Seq P1 CCC TTG AAC CTC CTC GTT CGA CC 
52 pMSCV Seq P2 GAG ACG TGC TAC TTC CAT TTG TC 
53 Abl T315I P1 AG CCC CCG TTC TAT ATC ATC ATT GAG TTC 
ATG ACC 
54 Abl T315I P2 GGT CAT GAA CTC AAT GAT GAT ATA GAA CGG 
GGG CT 
55 Abl Y253F P1 TG GGC GGG GGC CAG TTC GGG GAG G 
56 Abl Y253F P2 C CTC CCC GAA CTG GCC CCC GCC CA 
57 Abl E355G P1 A GCC ATG GAG TAC CTG GGG AAG AAA AAC 
TTC ATC C 
58 Abl E355G P2 G GAT GAA GTT TTT CTT CCC CAG GTA CTC CAT 
GGC T 
59 Abl H396R P1 C ACC TAC ACA GCC CGT GCT GGA GCC AAG T 
60 Abl H396R P2 A CTT GGC TCC AGC ACG GGC TGT GTA GGT G 
61 Abl H396P P1 C ACC TAC ACA GCC CCT GCT GGA GCC AAG T 
62 Abl H396P P2 A CTT GGC TCC AGC AGG GGC TGT GTA GGT G 
 
 
	   28	  
4.1.5 Plasmids  
Five plasmids were used in this study. pEG202 and pIN01 plasmids were used for Y2H assays. 
pET28a and pCDFDuet-1 plasmids were used to coexpress proteins in E. coli. pMSCV-YFP 
plasmid was used to express intein peptides in mammalian cells. Plasmid maps and details are 
given in Figures 4.1 to 4.5. The following plasmid maps were created using PlasMapper (Dong 
et al., 2004). 
 
     
Figure 4.1. pEG202 plasmid: pEG202 (GenBank accession U89960) was used as a bait 
plasmid in the lariat Y2H interaction trap. Targets were cloned between the EcoRI and XhoI 
restriction sites using homologous recombination. Cloned targets were expressed constitutively 
as a fusion to the LexA DNA binding domain (DBD) in EY111. The plasmid has yeast alcohol 
dehydrogenase promoter (yADH1 prom) and yeast alcohol dehydrogenase terminator (yADH1 
term) to promote and terminate transcription, respectively. The yeast 2µ origin enables 
autonomous replication of the plasmids in S. cerevisiae. An auxotrophic selectable marker 
(HIS3 gene) is used to select and maintain the vectors in yeast cells. The pBR322 origin allows 
for replication in E. coli and the ampicillin-resistance gene (amp marker) allows for selection in 
E. coli. 
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Figure 4.2. pIN01 plasmid (top) and the construct expressed from the plasmid (bottom): 
pIN01 was used as a prey plasmid in the lariat Y2H interaction trap. The plasmid contains Ssp-
IC and Ssp-IN domains separated by RsrII restriction site. The intein domains are cloned as C-
terminal fusions to the Y2H machinery present in the plasmid backbone. The RsrII site is used 
to clone peptide libraries into the plasmid. The galactose promoter (GAL1 prom) is used to 
drive the expression of intein peptides fused to the Y2H machinery. The construct expressed 
from the plasmid is shown in the bottom figure, where NLS, B42 AD and HA tag refer to     
nuclear localization sequence, B42 activation domain, and haemagglutinin tag, respectively. 
The plasmid has yeast alcohol dehydrogenase terminator (yADH1/2 term) to terminate 
transcription. The yeast 2µ origin enables autonomous replication of the plasmids in S. 
cerevisiae. An auxotrophic selectable marker (TRP1 gene) is used to select and maintain the 
vectors in yeast cells. The pBR322 origin allows for replication in E. coli and the ampicillin-
resistance gene (amp marker) allows for selection in E. coli. 
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Figure 4.3. pET28a plasmid: pET28a is an E. coli expression plasmid. Generally, the proteins 
are expressed with a N-terminal His tag-thrombin-T7 tag sequence and/or a C-terminal His tag 
sequence using this plasmid. Protein expression is controlled with an IPTG inducible promoter 
(T7 promoter). T7 terminator is used to terminate transcription. The pBR322 origin enables the 
replication of plasmids in E. coli. The kanamycin-resistance gene (kan2 marker) is used to 
select and maintain the vectors in the host. We used this plasmid to express human Abl SH3-
SH2-SH1 construct (residues 64-515 c-Abl 1b numbering) in E. coli. The construct was 
subcloned between the NdeI and XhoI restriction sites in the vector modified to yield a tobacco 
etch virus (TEV) protease cleavable N-terminal His tag. The modified pET28a-Abl SH3-SH2-
SH1 plasmid was kindly provided by Dr. John Kuriyan. 
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Figure 4.4. pCDFDuet-1 plasmid: pCDFDuet-1 is an E. coli expression plasmid designed for 
the coexpression of two proteins. The vector contains two T7 promoters and two multiple 
cloning sites (MCS). The T7 promoter is an IPTG inducible promoter. The T7 terminator is 
used to terminate transcription. There is a His tag sequence at the N-terminus of the MCS1 and 
a S-tag sequence at the C-terminus of the MCS2. CloDF13-derived CDF replicon enables the 
replication of plasmids in E. coli. The spectinomycin/streptomycin-resistance gene (Sm/SpR) is 
used to select and maintain the vectors in the host. We used this vector to coexpress Yersinia 
pestis tyrosine phosphatase (YopH) in E. coli with Abl kinase. YopH was subcloned between 
the NcoI (N-terminus to His tag and MCS1) and AvrII (MCS2) restriction sites in the plasmid 
to express an untagged YopH construct. His tagged Abl kinase was expressed from the pET28a 
vector (Figure 4.3). This YopH coexpression maintains the over-expressed tyrosine kinases in 
the dephosphorylated state and helps to overcome the toxic effects of protein tyrosine kinase 
activity in E. coli. The pCDFDuet-1-YopH plasmid was kindly provided by Dr. John Kuriyan. 
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Figure 4.5. pMSCV-YFP plasmid (top) and the gene of interest subcloned into the 
plasmid (bottom): pMSCV is a murine stem cell virus vector. Generally, pMSCV is used to 
produce high-titer, replication-incompetent, infectious retrovirus particles in packaging cell 
lines. These particles can infect target cells and transmit the gene of interest to them. Upon 
transfection, pMSCV can transiently or stably express a transcript containing the extended viral 
packaging signal Ψ+, a gene of interest, and the yellow fluorescent protein (YFP) marker. To 
achieve high-level gene expression in mammalian cells and hematopoietic/embryonic stem 
cells, the vector harbors a specifically designed 5' long terminal repeat (LTR) derived from the 
murine stem cell PCMV virus. The murine phosphoglycerate kinase (PGK) promoter controls 
expression of the YFP marker. The pBR322 origin allows for replication in E. coli and the 
ampicillin-resistance gene (amp marker) allows for selection in E. coli. The intein peptides with 
appropriate tags for detection at N- and C- termini (bottom figure) were directionally subcloned 
into the pMSCV vector using the EcoRI and XhoI restriction sites. The MSCV-YFP plasmid 
was kindly provided by Dr. Craig Jordan. 
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4.2 General Molecular Biology Protocols 
4.2.1 Agarose gel electrophoresis 
To visualize DNA or to determine the size of DNA, samples (PCR products/plasmids) 
were mixed with 6x loading dye (50% (v/v) glycerol, 0.2 M EDTA pH 8.3, 0.05% (w/v) 
bromophenol blue) to achieve a final dye concentration of 1x. The samples were resolved in an 
agarose gel consisting of 0.5 to 2% (w/v) ultrapure agarose in 1x TAE Buffer (40 mM Tris-
acetate, 1 mM EDTA, pH 8.0) and 0.5 µg/mL ethidium bromide. Gels were run at a constant 
voltage between 150-200 V for 20 to 40 minutes in 1x TAE Buffer and photographed using a 
UV light transilluminator (Bio-Rad). 
4.2.2 DNA Purification 
PCR products and restriction enzyme digested plasmids were purified using PCR clean-
up kit (Qiagen/Bio-Basic) and gel purification kit (Qiagen/Bio-Basic), respectively, according 
to manufacturer’s instructions.  
4.2.3 Site directed mutagenesis 
Mutations were generated in the pEG202-Abl SH1 plasmid using Quikchange II XL site 
directed mutagenesis kit (Stratagene) as per manufacturer’s directions. All mutations were 
confirmed by sequence analysis. Mutagenic primers (oligonucleotides 53-62) and sequencing 
primers (oligonucleotides 1 and 2) are listed in Table 4.4.  
4.2.4 DNA sequencing 
Samples (plasmids/PCR products) were sent to the Plant Biotechnology Institute, 
National Research Council of Canada for sequencing. 
4.2.5 SDS- PAGE and Western analysis 
Samples for SDS-PAGE were prepared by suspending the proteins or E. coli cells in 4x 
SDS loading dye (240 mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 8% (w/v) SDS, 16% (v/v) 2- 
mercaptoethanol, 0.01% (w/v) bromophenol blue). Samples from yeast cells were prepared in 
the same way except that the cells were first suspended in 200 µL of 0.1 M NaOH and 
incubated for 5 min at room temperature. Prior to loading, all samples were boiled for 5 min 
and cooled. 
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 SDS-PAGE was performed as described by Laemmli (Laemmli, 1970) using a Mini-
Protean 3 electrophoresis unit (Bio-Rad). Briefly, sample fractions were resolved on a 4-12% 
polyacrylamide gel in 1x running buffer (25 mM Tris-HCl pH 8.3, 190 mM glycine, 0.1% 
(w/v) SDS) at a constant voltage of 200 V for 45 min. A 4% stacking gel contained 0.125 M 
Tris-HCl pH 6.8, 0.1% SDS, 4% degassed acrylamide:bis-acrylamide (37.5:1), 0.1% (v/v) 
TEMED, and 0.05% (w/v) ammonium persulphate. A 12% resolving gel contained 0.375 M 
Tris-HCl pH 8.8, 0.1% SDS, 12% degassed acrylamide:bis-acrylamide (37.5:1), 0.05% (v/v) 
TEMED, and 0.05% (w/v) ammonium persulphate.  
To visualize total proteins by Coomassie-staining, SDS-PAGE gels were incubated in 
staining solution (0.12% (w/v) Coomassie Brilliant Blue R-250, 50% methanol, 10% acetic 
acid) for 2 hours, and washed with destaining solution (40% methanol, 10% acetic acid) for 
several hours to overnight. Destained gels were visualized and photographed using a Gel-Doc 
imager (Bio-Rad). 
  To visualize specific proteins by Western analysis, proteins were transferred from SDS-
PAGE gels to nitrocellulose membranes (Bio-Rad) using a semi-dry electrophoretic transfer 
cell (Trans-Blot). Transfer was performed at a constant voltage of 15 V for 20 min in the 
presence of transblot buffer (48 mM Tris-HCl pH 8.3, 39 mM glycine, 20% (v/v) methanol, 
0.04% (w/v) SDS). Membranes were blocked with Odyssey blocking buffer (LI-COR 
Biosciences) for 1 hour at room temperature, and incubated overnight with primary antibody 
(diluted in Odyssey blocking buffer) at 4 °C. Membranes were washed 3 times with PBT (PBS 
with 0.1% Tween-20) and incubated with a fluorescently labeled secondary antibody (diluted in 
Odyssey blocking buffer) for 1 hour at room temperature. Membranes were washed two times 
with PBT, and one time with PBS. The blots were visualized and quantified using an Odyssey 
infrared imager (LI-COR Biosciences). 
4.3 General E. coli Protocols 
4.3.1 Propagation of E. coli 
Standard procedures were used to culture and propagate E. coli (Elbing and Brent, 
2002). Lysogeny broth (LB) was prepared with 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
85.6 mM NaCl, and 1 mM NaOH in ddH2O.  Solid media contained 2% (w/v) agar. Ampicillin 
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was used at 100 µg/mL concentration. Kanamycin, spectinomycin and chloramphenicol were 
used at 50 µg/mL concentration.  
4.3.2 Preparation of plasmid DNA from E. coli 
Plasmid mini-preparation kits (Qiagen/Bio-Basic) and maxi-preparation kits (Qiagen) 
were used as described by the manufacturer. 
4.3.3 E. coli transformation 
Electrocompetent cells were prepared as described by Ausubel et al., 1988. Briefly, a 
fresh bacterial colony was transferred into 5 mL of LB media and grown overnight at 37 °C. 
The culture was diluted in 500 mL LB to an OD600 of 0.1–0.2 and allowed to reach an OD600 of 
0.6–0.8. The cells were harvested and washed twice with 250 mL of ice cold ddH2O by 
centrifugation at 4,000 x g for 20 min at 4 °C.  The cells were washed finally with 20 mL of ice 
cold ddH2O by centrifugation at 4,200 x g for 10 min at 4 °C. The cells were resuspended in 
one pellet volume of ice-cold 10% (v/v) glycerol and aliquots of 50 µL were stored at −80 °C.  
Electrocompetent cells were transformed with plasmids by electroporation. Briefly, 1 
µL of plasmid (50-150 ng/µL) was mixed with 50 µL of electrocompetent cells, and the mixture 
was transferred into an electroporation cuvette. The cuvette was subjected to a short electric 
pulse (field strength = 12.5 kV/cm) using a gene pulser (Bio-Rad). The cells were recovered 
immediately, transferred into 1 mL of pre-warmed LB media and incubated for 30 min at 37 
°C. The cells were harvested and plated onto LB agar plates containing the appropriate 
antibiotic. 
4.4 General Yeast Protocols 
4.4.1 Propagation of yeast 
Standard procedures were used to culture and propagate S. cerevisiae (Geyer and Brent, 
2000). Rich media (YPDA) was prepared with 1% (w/v) yeast extract, 2% (w/v) peptone, 80 
mg/L adenine, and 2% (w/v) dextrose. Complete synthetic media (CSM) was prepared with 
0.67% (w/v) yeast nitrogen base without amino acids, appropriate CSM supplement mix, and 
either 2% (w/v) dextrose or a combination of 2% (w/v) galactose and 1% (w/v) raffinose. X-gal 
media was supplemented with 0.008% X-gal (dissolved in 100% dimethylformamide) and 1× 
BU salts (25 mM sodium phosphate buffer pH 7.0). Solid media contained 2% agar. 
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4.4.2 Preparation of plasmid DNA from yeast 
Plasmids were isolated from yeast using the "smash and grab" procedure (Hoffman and 
Winston, 1987). Briefly, a yeast colony was transferred into 2 mL of appropriate synthetic 
amino acid dropout media and grown overnight at 30 °C. The culture was centrifuged at 18,000 
x g for 30 seconds. The cells were resuspended in 200 µL breaking buffer (2% (v/v) Triton X-
100, 1% (v/v) SDS, 100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA) followed by the 
addition of 300 µg glass beads and 200 µL phenol-chloroform-isoamylalcohol (25:24:1, v/v/v). 
The mixture was vortexed vigorously for 2 min and centrifuged at 18,000 x g for 5 min. 50 µL 
of the aqueous layer was collected and stored at – 20 °C. 
4.4.3 Yeast transformation 
Yeast competent cells were prepared according to the procedure described by Gietz and 
Schiestl in 2007. Briefly, a fresh yeast colony was transferred into 5 mL of appropriate media 
and grown overnight at 30 °C. The culture was diluted in 500 mL of appropriate media to an 
OD600 of 0.1–0.2 and allowed to reach an OD600 of 0.6–0.8. The cells were harvested and 
washed once with 250 mL of sterile ddH2O by centrifugation at 3,000 x g for 5 min at 20 °C. 
The cells were resuspended in 5 ml of sterile frozen competent cell (FCC) solution (5% v/v 
glycerol, 10% v/v DMSO) and aliquots of 50 µL were stored at −80 °C. 
Yeast competent cells were transformed with plasmids using the lithium acetate 
transformation procedure (Gietz and Schiestl, 2007). Cell samples (50 µL FCC aliquots) were 
thawed at 37 °C for 30 seconds and centrifuged at 13,000 x g for 2 min at 20 °C. The FCC 
solution (supernatant) was removed and the pellet was overlaid with 260 µL of 50% (w/v) 
polyethylene glycol 3350, 36 µL of 1 M LiOAc, 50 µL of 2 mg/mL single-stranded DNA, 0.1-1 
µg plasmid (digested/undigested) and PCR insert (optional). The mixture was vortexed 
vigorously to resuspend the pellet, incubated for 30 min at 30 °C and heat shocked for 15 min 
at 42 °C. The sample was centrifuged at 13,000 x g for 30 seconds and the supernatant was 
removed. The pellet was resuspended in 100 µL ddH2O and plated onto appropriate media. 
4.5 Manipulation of the pIN01 plasmid 
We manipulated pIN01 to derive plasmids that express desired inactive, lariat and linear 
peptides, and to construct random and focused libraries in yeast. A brief description about 
pIN01 is given in section 4.1.5.  
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4.5.1 Construction of inactive intein plasmids 
To construct plasmids that express A1, A2, TG17 and TG18 inactive intein constructs, 
we PCR amplified oligonucleotides 5, 6, 45 and 46, respectively, using oligonucleotides 9 and 
10 as primers. PCR reactions were performed in a 50 µL volume containing 1X PCR buffer (60 
mM Tris-SO4 (pH 8.9), 18 mM (NH4)2SO4), 2 mM MgSO4, 200 µM dNTPs, 0.4 µM forward 
primer, 0.4 µM reverse primer, 4 nM oligonucleotide template, and 1 Unit Platinum® Taq DNA 
Polymerase High Fidelity. The reaction mixtures were subjected to ten amplification cycles 
consisting of a denaturing step at 94 °C for 30 seconds, an annealing step at 50 °C for 30 
seconds, and an extension step at 68 °C for 15 seconds. pIN01 was digested with RsrII (New 
England Biolabs) according to manufacturer’s directions and the digested plasmid was gel-
purified. PCR products were cloned into RsrII-cut, gel-purified pIN01 using in vivo 
homologous recombination (Ma et al., 1987; Hua et al., 1997) in EY93. Lithium acetate 
transformations were performed as described earlier, with each transformation containing 30 
µL of PCR product and 0.25 µg of RsrII-cut, gel-purified pIN01. Resulting plasmids were 
isolated from yeast, transformed into E. coli, amplified, purified, and sequenced (using 
oligonucleotides 3 and 4).  
4.5.2 Construction of linear peptide plasmids 
To construct plasmids that express A1, A2, TG17 and TG18 linear peptides, we PCR 
amplified oligonucleotides 7, 8, 47 and 48, respectively, using oligonucleotides 9 and 11 as 
primers. PCR reactions were performed as described in section 4.5.1. pIN01 was digested with 
RsrII and XhoI (New England Biolabs) according to manufacturer’s directions, the two 
fragments were separated by gel electrophoresis, and the larger fragment was gel purified. PCR 
products were cloned into the gel-purified pIN01 fragment using in vivo homologous 
recombination (Ma et al., 1987; Hua et al., 1997) in EY93. Lithium acetate transformations 
were performed as described earlier, with each transformation containing 30 µL of PCR 
product and 0.25 µg of purified pIN01 fragment. Resulting plasmids were isolated from yeast, 
transformed into E. coli, amplified, purified, and sequenced (using oligonucleotides 3 and 4).  
4.5.3 Construction of site saturation libraries 
To construct nine site saturation libraries corresponding to nine residues 
(GWQRLPFEY) of the A1 lariat, we sequentially randomized each residue of the lariat starting 
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from glycine to tryptophan, using oligonucleotides numbered from 13 to 21, respectively. 
Oligonucleotides 13 to 21 were PCR amplified using oligonucleotides 22 and 23 as primers. 
PCR products were cloned into RsrII-cut, gel-purified pIN01 using in vivo homologous 
recombination (Ma et al., 1987; Hua et al., 1997) in EY93. PCR reactions and cloning of PCR 
products into the library vector were performed as described in section 4.5.1.  
4.5.4 Construction of third-generation constructs 
To construct plasmids that express third-generation lariat constructs named from TG1 to 
TG18 (18 different constructs), we PCR amplified oligonucleotides numbered from 24 to 41, 
respectively, using oligonucleotides 22 and 23 as primers. PCR products were cloned into 
RsrII-cut, gel-purified pIN01 using in vivo homologous recombination (Ma et al., 1987; Hua et 
al., 1997) in EY93. PCR reactions and cloning of PCR products into pIN01 were performed as 
described in section 4.5.1.  
To construct plasmids that express ∆E8-A1, ∆N8-TG17 and ∆N8-TG18 lariat 
constructs, we PCR amplified oligonucleotides 42, 43 and 44, respectively, using 
oligonucleotides 22 and 23 as primers. PCR products were cloned into RsrII-cut, gel-purified 
pIN01 using in vivo homologous recombination (Ma et al., 1987; Hua et al., 1997) in EY93. 
PCR reactions and cloning of PCR products into pIN01 were performed as described in section 
4.5.1.  
4.6 Yeast two-hybrid protocols 
4.6.1 Y2H Screening 
Y2H screens were conducted using the lariat Y2H interaction trap (Barreto et al., 2009). 
Targets were cloned as a fusion to LexA DNA binding domain in the Y2H bait vector pEG202 
and expressed in the MATα strain EY111. EY111::pEG202 was cultured in SD H-media to an 
OD600 of 0.6–0.8. The combinatorial lariat libraries were constructed in the Y2H prey vector 
pIN01 and harbored in the MATa strain EY93. EY93::pIN-01 cells were scraped off the SD W- 
plates using a sterile glass microscope slide and grown in SD W- media to an OD600 of 0.6–0.8. 
Prior to mating, viability and processing of the library members were analyzed. EY93::pIN-01 
cells were mixed with EY111::pEG202 cells at a ratio of 1:20, pelleted by centrifugation, 
resuspended in YPDA media and spread on YPDA plates. Plates were incubated at 30 °C for 
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24 hours. Mated cells were scraped off the plates, washed with PBS, resuspended in glycerol 
freeze down solution (25 mM Tris-HCl pH 8.0, 65% (v/v) glycerol, 0.1 M MgSO4) and stored 
at – 80 °C. A sample of the library was thawed and serial dilutions were plated onto SD H-, SD 
W-, SD H-W-, SGR H-W-L- and SGR H-W-A- Xgal+ plates to calculate the mating efficiency 
of the yeast cells and to determine the optimal cell density for performing Y2H screens. Once 
the optimal conditions were determined, an aliquot of the mated cells was thawed, suspended in 
SGR H-W- media, incubated at 30 °C for six hours, and plated onto SGR H-W-L- and SGR H-
W-A- Xgal+ selection plates. These plates were incubated at 30 °C for three to five days. 
Colonies (positive hits) were picked off the selection plates, grown overnight in SD H-W- 
media, harvested by centrifugation, resuspended in glycerol freeze down solution and stored at 
– 80 °C.  
4.6.2 Rechecking Y2H interactions 
Using the “smash and grab” technique, plasmids were isolated from the positive hits. 
The noose region in the prey plasmids was amplified by PCR using oligonucleotides 9 and 10 
as primers. PCR reactions were performed as described in section 4.5.1. PCR products were 
recloned into RsrII-cut, gel-purified pIN01 using in vivo homologous recombination (Ma et al., 
1987; Hua et al., 1997) in EY93. Lithium acetate transformations were performed as described 
earlier, with each transformation containing 30 µL of PCR product and 0.25 µg of gel-purified 
pIN01 fragment. Three to five individual colonies from each yeast transformation were selected 
and mated to EY111 cells containing the appropriate target.  Diploids were selected on SD H-
W- plates and plated onto SGR H-W-L- and SGR H-W-A- Xgal+ plates to estimate the 
strength of interactions. Plasmids were isolated from positive colonies, which conferred strong 
and specific interactions. The intein peptide in the prey plasmids was amplified by PCR using 
oligonucleotides 3 and 4 as primers. PCR reactions were performed in a 50 µL volume 
containing 1X PCR buffer (60 mM Tris-SO4 (pH 8.9), 18 mM (NH4)2SO4), 2 mM MgSO4, 200 
µM dNTPs, 0.4 µM forward primer, 0.4 µM reverse primer, 50 ng plasmid DNA, and 1 Unit 
Platinum® Taq DNA Polymerase High Fidelity. The reaction mixtures were subjected to a 5 
min initial denaturation step at 94 °C followed by 25 cycles of amplification. Each cycle 
contained a denaturing step at 94 °C for 30 seconds, an annealing step at 50 °C for 30 seconds, 
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and an extension step at 68 °C for 60 seconds. PCR products were cleaned up and sequenced 
(using oligonucleotides 3 and 4) to determine the sequence of the interacting lariat. 
4.6.3 Beta-Galactosidase assay 
Yeast cells containing bait and prey plasmids were grown overnight in SGR H-W- 
media. The culture was diluted to an OD600 of 0.1–0.2 and allowed to reach an OD600 of 0.6–
0.8. 1.2 mL of the culture was centrifuged at 18,000 x g for 5 min. The pellet was resuspended 
in 1 mL of Z buffer without 2-mercaptoethanol (0.06 M Na2HPO4.7H2O, 0.04 M 
NaH2PO4.H2O, 0.01 M KCl, 0.001 M MgSO4) and centrifuged again as in the previous step. 
The resulting pellet was resuspended in 150 µL of Z buffer with 2-mercaptoethanol (0.06 M 
Na2HPO4.7H2O, 0.04 M NaH2PO4.H2O, 0.01 M KCl, 0.001 M MgSO4, 0.05 M 2-
mercaptoethanol), 50 µL of chloroform and 20 µL of 0.1% SDS, and this mixture was vortexed 
vigorously. 700 µL of ortho-nitrophenyl-β-galactopyranoside (1 mg/mL in Z buffer with 2-
mercaptoethanol) was added to the mixture and the reaction was started. The reaction was 
incubated at 30 °C until a color change was observed from white to medium yellow. The 
reaction was stopped by adding 500 µL of 1 M Na2CO3 and then centrifuged at 18,000 x g for 
10 min. OD420 of the supernatant was measured using a microplate reader (Spectramax M5)  
and the β-galactosidase activity was calculated in Miller units according to the formula:  Miller 
unit = (A420) (1000) / (time) (volume) (A600), where time is reaction time in minutes and 
volume is reaction volume in mL. 
4.7 In vitro studies 
To perform in vitro kinase assays, binding and structural studies, we expressed and 
purified His-tagged human c-Abl SH3-SH2-SH1 (residues 64-515 Abl1b numbering) construct 
using a bacterial expression system as described previously (Seeliger et al., 2005). Briefly, 
pET28a-Abl SH3-SH2-SH1 and pCDFDuet-1-YopH vectors (plasmid maps and details in 
section 4.1.5) were transformed into BL21C+ E. coli cells. Yersinia pestis tyrosine phosphatase 
(YopH) was co-expressed in order to maintain the tyrosine kinases in the dephosphorylated 
state. Positive transformants were grown to OD600 of 1.2 in expression media (TB with 50 
µg/mL kanamycin and 50 µg/mL spectinomycin) at 37 °C. The expression of recombinant 
proteins was induced with 0.25 mM IPTG for 16 hours at 18 °C. Cells were harvested and 
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lysed by French press in buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% (v/v) glycerol, 
2 mM DTT, 10 mM imidazole, 1 % (v/v) protease inhibitor cocktail (Sigma-Aldrich)). Cleared 
lysates were mixed gently with Ni-NTA slurry (Qiagen) for 30 min at 4 °C. The mixture was 
loaded into a column and the column was washed 3 times with buffer B (50 mM Tris-HCl pH 
8.0, 500 mM NaCl, 10% (v/v) glycerol, 1 mM DTT, 10 mM imidazole). Kinase fractions were 
eluted with buffer C (buffer B plus 40 mM imidazole) and dialyzed against 20 volumes of 
buffer D (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 1 mM DTT) with a 13-
kDa molecular weight cutoff membrane for 16 hours at 4 °C. The dialyzed protein was diluted 
and loaded onto an anion exchange column (Hitrap Q FF, GE Life Sciences) equilibrated with 
buffer E (20 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 1 mM DTT). Proteins were eluted with 
a linear gradient of 0–35% buffer F (buffer E plus 1 M NaCl). Kinase fractions were pooled, 
concentrated and loaded onto a gel-filtration column (Sephacryl S-100, GE Life Sciences) 
equilibrated with buffer G (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 1 mM 
DTT). Proteins were eluted from the column using the same buffer (G). The major peak 
containing Abl Kinase was pooled, concentrated and stored at – 80 °C. 
Kinetic analysis of Abl kinase inhibition by synthetic peptides was carried out using a 
continuous spectroscopic kinase assay (Boerner et al., 1995). This assay couples the 
phosphorylation of substrate peptide and production of ADP to the oxidation of NADH through 
phosphoenolpyruvate, pyruvate kinase, and lactate dehydrogenase (Barker et al., 1995). The 
reaction mixture contained 100 mM Tris-HCl pH 8.0, 10 mM MgCl2, 75 U pyruvate kinase 
(Sigma-Aldrich), 105 U lactate dehydrogenase (Sigma-Aldrich), 1 mM phosphoenolpyruvate 
(Sigma-Aldrich), 846 µM NADH (Sigma-Aldrich), 60 nM Abl kinase, and fixed or varied 
concentrations of ATP, Abl peptide substrate (EAIYAAPFAKKK; Genscript) and inhibitory 
peptide in a total volume of 75 µL. Reaction mixtures for dose response assays contained a 
fixed concentration of ATP (2.2 mM) and Abl peptide substrate (350 µM). The assays were 
performed in 96-well plates and initiated with the addition of Abl kinase. Absorbance data were 
collected every 30 s at 340 nm with a microplate reader (SpectraMax M5). To calculate Abl 
kinase activity, initial rates of change in A340 were drawn from the slopes of A340 curves and 
equated to the moles of NADH oxidized per unit time using the extinction coefficient of 
NADH (6.2 × 103). To determine IC50 of inhibitory peptides, the values from individual 
samples were analyzed and plotted as a function of drug concentration. Ki value was calculated 
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from the IC50 value and concentration of ATP in the assay (2.2 mM) according to the Cheng-
Prusoff relationship: Ki = IC50 / (1 + {[ATP]/Km}) where Km is the Michaelis Menton constant 
for ATP, which was determined to be 70 µM for the Abl Kinase. To determine kinetic 
parameters (Km and Vmax), the values from individual samples were analyzed and fit to the 
Michaelis–Menten equation using Prism (GraphPad). 
Fluorescence analysis of binding of ligands to the Abl myristoyl pocket was carried out 
using a F2500 fluorescence spectrophotometer (Hitachi). GNF2, a myristate competitive small 
molecule inhibitor of Abl kinase (Adrian et al., 2006), fluoresces at 407 nm upon binding to the 
protein. Increasing amounts of ligands (A1 lariat or myristic acid) were titrated to the Abl-
GNF2 complex (0.18 µM Abl+0.3 µM GNF2 in 20 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 
100 mM NaCl, 1 mM DTT), and the ability of the ligands to displace GNF2 from the Abl 
myristoyl pocket was examined by monitoring the fluorescence at 407 nm. All titrations were 
carried out in a quartz cuvette (Starna cells) at 20 ± 2 °C. A wavelength of 295 nm was used for 
excitation and the emission was recorded between 310 and 550 nm. A slit of 2.5 nm was used 
for excitation and emission. The decrease in fluorescence at 407 nm was fit to the one-site 
competition binding equation for determining the IC50 value. 
Kinase selectivity analysis was carried out using an ATP site-dependent in vitro 
competition-binding assay (KinexTM Protein Kinase Microarray-200). The assay evaluated the 
selectivity of the synthetic TG17 lariat against a panel of 200 distinct kinases, which included 
36 AGC kinases, 30 calmodulin dependent protein kinases (CAMK), 29 CMGC kinases, 20 
STE kinases, 61 tyrosine kinases (TK), nine tyrosine kinase-like (TKL) proteins, two lipid 
kinases (LK), and 13 other kinases. Briefly, the lariat was incubated with a biotinylated ATP 
probe on the protein kinase microarray. If the lariat binds to the kinase and directly or indirectly 
occludes the ATP binding pocket, then fewer probes can covalently bind to the ATP site. If the 
lariat does not bind to the kinase, there is no reduction in the binding of probes to the ATP site. 
The results were read out by quantifying the amount of ATP probe bound to the kinases using 
fluorescently labeled streptavidin conjugates. To obtain relative binding scores (RBS), binding 
data were fit to the following equation: RBS = {(1-FP) [D] FD}/ (FP-FD), where FP is the 
fraction of the probe bound to the kinase, FD is the fraction of the lariat bound to the kinase, 
and [D] is the lariat concentration (10 µM). Kinases that had a relative binding score of less 
than 50% of the DMSO control were predicted as non-binders.  
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4.8 Cell biological studies 
Cell biological studies were conducted with K562 cells (erythrocytic cell type, triploid, 
multiple t(9;22) translocations, b3-a2 Bcr-Abl fusion). K562 (CCL243) was obtained from 
ATCC and cultured in IMDM (Iscove’s Modified Dulbecco’s Media) supplemented with 10% 
fetal calf serum, 100 IU/ml penicillin and 100 mg/ml streptomycin. Cells were grown at 37 °C 
with 5% CO2. 
To express intein peptides in K562 cells, we first subcloned the intein peptides into the 
pMSCV vector (plasmid map and details in Figure 4.5). The intein peptides were PCR 
amplified from Y2H prey plasmids using oligonucleotides 49 and 50 as primers. PCR reactions 
were performed as described in section 4.6.2. PCR products were digested with EcoRI and 
XhoI (New England Biolabs) and cloned into pMSCV using standard restriction enzyme based 
cloning procedures (Ausubel et al., 1997).  Resulting plasmids were sequence verified using 
oligonucleotides 51 and 52 as primers. 
Transient transfections of pMSCV vectors into K562 cells were carried out using the 
cell line nucleofector system (Amaxa Biosystems) according to manufacturer’s directions. 
Briefly, 1 × 106 cells were suspended in 100 µL nucleofector solution, mixed with 5 µL of 
plasmid DNA (1 µg/µL in TE buffer) and subjected to nucleofection using the program T-016. 
Analysis of transfection efficiency was carried out by flow cytometry. To assess cell viability, 
cells were stained with trypan blue reagent and counted using a hemocytometer. For Western 
analysis, K562 cells were harvested 24 hours post-nucleofection, washed twice with PBS, and 
lysed in SDS-PAGE loading buffer (62.5 mM Tris-HCl pH 6.8, 10% (v/v) glycerol, 2.3% (w/v) 
SDS, 5% (v/v) 2- mercaptoethanol, 0.002% (w/v) bromophenol blue). Lysates were subjected 
to SDS-PAGE and immunoblotting as described in section 4.2.5. 
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5. Results and Discussion 
Since there are no ATP competitive peptide inhibitors of protein kinases, and 
considering that such inhibitors could identify new allosteric drug-binding pockets in the kinase 
catalytic cleft, we started a project to isolate and characterize a novel class of cyclic peptides, 
referred to as lariats, against Abl kinase, a drug target important in CML and other disorders. 
Several aspects prompted us to employ the lariat peptide system as a screening method for the 
identification of peptide inhibitors of kinases. First, lariats possess a lactone constraint. 
Constrained peptides bind to targets with higher affinity than their linear counterparts 
(Koivunen et al., 1994; McConnell et al., 1994; Colas et al., 1996). In addition, without 
exposed N and C termini, constrained peptides are not open to degradation by cellular 
exoproteases (Horswill and Bencovic, 2005). Second, lariats are easily and rapidly generated 
against any target in a cost-effective manner. This is in contrast to isolating linear/cyclic 
peptides from synthetic peptide libraries, which incur huge investment of time and money 
(Horswill and Bencovic, 2005). Third, lariat screens are conducted in eukaryotic cells. This 
circumvents the problems associated with the large-scale purification of target proteins. 
Furthermore, this approach should select for peptides that are stable and functional under 
intracellular conditions. In contrast, phage display requires pure targets to conduct screens, and 
a substantial proportion of molecules selected from phage display turn out to be either unstable 
or non-functional in eukaryotic cells (Cattaneo and Biocca, 1999; Hoppe-Seyler et al., 2001). 
Fourth, lariats are amenable to chemical synthesis, and synthetic lariats are well suited for in 
vitro studies. This property of lariats makes them advantageous over peptide aptamers and 
other scaffolded peptides, which are only over-expressed and purified (Borghouts and Weiss, 
2009). Fifth, lariats are easily extended to cell biological and animal studies. Once the DNA 
sequences of interacting lariats are identified by genetic selection, the genes coding for intein 
peptides are transferred from the Y2H vector to appropriate mammalian vectors, and delivered 
into cells through transfection or viral infection. Sixth, chemical moieties such as affinity tags, 
fluorescent molecules, localization sequences and membrane permeable peptides can be easily 
attached to the N-terminus of synthetic/recombinant lariats. This property of lariats gives them 
advantages over “head-to-tail” cyclized peptides that have no free end to attach moieties 
(Barreto et al., 2009).  
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5.1 Isolation and mechanism of action of Abl SH1-interacting lariats 
5.1.1 Library screening  
 To identify lariats interacting with the Abl SH1 domain, we first cloned the target (human 
Abl1b residues 210-496) as a fusion to the LexA DNA binding domain in the Y2H bait vector 
pEG202 and expressed it in the MATα strain EY111. As prey constructs, we used members of 
the combinatorial Ssp-Ssp R7 lariat library expressed in the MATa strain EY93. 
 The Ssp-Ssp R7 library was constructed using the pIN01 plasmid. This plasmid codes for 
the IC and IN domains of the Synechocystis sp. PCC6803 (Ssp) DnaE intein with specific 
mutations for lariat production, in addition to other domains required for Y2H assays, 
replication, and selection. The random region of the peptide library was cloned between the 
permutated intein domains for facilitating the formation of lariat peptides. With seven random 
positions, the Ssp-Ssp R7 library displays the amino acid sequence SX7EY in the noose region 
of the lariat. Serine was included at the IC-peptide junction to catalyze a transesterification 
reaction that releases the IN domain and produces the lariat (Scott et al., 2001).  Glutamic acid 
and tyrosine were included in the noose region to facilitate lariat formation (Naumann et al., 
2005). Random amino acids were generated using the degenerate NNK codon, which encodes 
32 triplets that code for 20 different amino acids and one stop codon. The NNK codon was used 
for randomization in order to maximize the diversity of amino acids with a minimum number 
of stop and redundant codons (Wong et al., 2006).   
  The Ssp-Ssp R7 library contains ~20 million members. Sequencing analysis showed that 
~31% of library members contain correct sequences. Western blot analysis showed that ~70% 
of library members with correct sequences process to form the lariat. In total, ~25% of the 
library is capable of producing a lariat (Barreto et al., 2009). To ensure a 95% probability of 
screening a library with ~20 million members, we mated 20 copies of the library in the strain 
EY93 to the strain EY111, which expresses the target and contains the Y2H reporter genes. The 
diploids were screened for positive interactions based on the activation of LEU2, ADE2, and 
LacZ reporter genes using the lariat Y2H interaction trap. Two unique lariat sequences were 
isolated in the screen: A1 (SGWQRLPFEY) and A2 (SGWHRLSEEY), which interact with 
Abl SH1 but not with control proteins or other Bcr-Abl domains. Within the random region, the 
lariats have four residues in common: G1, W2, R4, and L5. One or more of these residues 
could play an important role in contributing to Abl SH1-lariat interactions.  
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5.1.2 In vitro studies with the synthetic A1 lariat 
	   We chose one of the two lariats, A1, for further characterization. To determine the 
mechanism of Abl kinase inhibition by the A1 lariat, we performed in vitro kinetic and binding 
experiments using the purified His-tagged human c-Abl kinase (residues 64-515 Abl1b 
numbering) and the synthetic A1 lariat. A truncated version of the A1 lariat was synthesized 
with an alanine at the N-terminus “tail” replacing the IC domain in the A1 lariat. The lariat 
version of the peptide was created by cyclizing the side chain of serine and the C-terminal 
carboxylic acid via an ester bond (A-[SGWQRLPFEY]).  
Kinetic analysis was carried out using a continuous spectroscopic kinase assay (Boerner 
et al., 1995). This assay couples the phosphorylation of substrate peptide and production of 
ADP to the oxidation of NADH through phosphoenolpyruvate, pyruvate kinase, and lactate 
dehydrogenase (Barker et al., 1995). First, we performed a dose-response analysis to assess the 
inhibitory activity of the A1 lariat. The dose response curve showed the IC50 and Ki of the A1 
lariat to be 193 µM and 5.95 µM, respectively (Figure 5.1a). Second, we examined the effects 
of increasing concentrations of ATP or substrate peptide on the inhibitory activity of the A1 
lariat. Incubation of Abl kinase with the A1 lariat in the presence of increasing concentrations 
of ATP resulted in an increase in Km for ATP, while not affecting Vmax of the reaction, which is 
the characteristic of competitive inhibition, indicating that the A1 lariat inhibits kinase activity 
in an ATP dependent manner (Figure 5.1b). Incubation of Abl kinase with the A1 lariat in the 
presence of increasing concentrations of substrate peptide resulted in a decrease in Vmax of the 
reaction, while not affecting Km for substrate peptide, which is the characteristic of non-
competitive inhibition, indicating that the A1 lariat inhibits kinase activity in a substrate-
independent manner (Figure 5.1c).  
Next, to verify whether the A1 lariat targets the myristate-binding site of Abl kinase, we 
carried out a fluorescence analysis of the binding of ligands (A1 lariat/myristic acid) to the Abl 
myristoyl pocket by titrating increasing amounts of ligands to the Abl-GNF2 complex. GNF2 is 
a myristate competitive small molecule inhibitor of Abl kinase (Adrian et al., 2006), which 
fluoresces at 407 nm upon binding to the protein. Myristic acid, included as a positive control, 
displaced GNF2 from the Abl-GNF2 complex with an IC50 of 12.5 ± 1.3 µM. The lariat was 
unable to displace GNF2, making IC50 calculations impossible, indicating that A1 does not bind 
to the myristate-binding pocket of the Abl kinase (Figure 5.1d).  
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Figure 5.1. Steady-state kinetic analysis of Abl kinase inhibition by the synthetic A1 
lariat: (a) Inhibitory activity of the A1 lariat. Recombinant c-Abl SH3-SH2-kinase was mixed 
with different concentrations of the A1 lariat, and kinase assays were performed using Abltide 
as a substrate.  The values from individual samples were analyzed and plotted as a function of 
drug concentration to determine the IC50 of the A1 lariat. Ki was calculated from the IC50 value 
using the Cheng-Prusoff relationship (see methods). (b) Effect of increasing concentrations of 
ATP on the inhibitory activity of the A1 lariat. The curves represent calculated best fits to the 
Michaelis–Menton equation with a constant amount of Abltide and various amounts of ATP 
and the A1 lariat. (c) Effect of increasing concentrations of Abltide on the inhibitory activity of 
the A1 lariat.  The curves represent calculated best fits to the Michaelis–Menton equation with 
a constant amount of ATP and various amounts of Abltide and the A1 lariat. (d) Fluorescence 
analysis of binding of the A1 lariat to Abl myristoyl pocket. Increasing amounts of ligands (A1 
lariat or myristic acid) were titrated to Abl-GNF2 complex and the ability of the ligands to 
displace GNF2 from the Abl myristoyl pocket was examined by monitoring the fluorescence at 
407 nm. The decrease in fluorescence at 407 nm was fit to the one-site competition binding 
equation for determining the IC50 value. All experiments were repeated at least twice and 
representative graphs are shown. 
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Together, the results from in vitro studies provide evidence that the A1 lariat is an ATP 
competitive inhibitor of Abl kinase. However, it cannot be concluded from these studies that 
the A1 lariat occupies the ATP binding pocket. This is because, in addition to ATP binding site 
inhibitors, allosteric inhibitors targeting a large additional cavity adjacent to the ATP binding 
pocket can still remain ATP competitive in kinetic analysis (Morphy, 2010). As the A1 lariat is 
comparatively larger than any typical type I/II kinase inhibitor, there are more chances for the 
lariat to target additional sites on the catalytic cleft outside the ATP binding site.  
There are several explanations as to why the catalytic cleft, but not other epitopes of 
Abl kinase, is targeted by the lariat.  First, the activation loop of Abl kinase is phosphorylated 
in yeast (data not shown), which causes the kinase to adopt an active conformation. In the 
active state, the catalytic cleft is wide open to accept Mg-ATP (Huse and Kuriyan, 2002; Nolen 
et al., 2004, Levinson et al., 2006), and this open conformation may favor the interaction of 
lariats with the catalytic cleft. Indeed, the preponderance of ATP-competitive small molecules 
over substrate-competitive/allosteric inhibitors is a consequence of using enzymatic assays to 
screen compound-libraries, which use highly active recombinant kinase domains, and maintain 
a low ATP concentration (Liu and Gray, 2006). Second, in order to compete with substrate 
proteins, lariat sequences should closely resemble kinase recognition motifs and adopt a 
“substrate-like” conformation, which may not be possible in the presence of a lactone 
constraint. In fact, most peptide inhibitors of kinases, which compete with substrate proteins, 
targeting proteins or docking sites are synthetic linear peptides that are rationally designed from 
kinase recognition motifs (Kaidanovich-Beilin and Eldar-Finkelman, 2006; Eldar-Finkelman 
and Eisenstein, 2009). Third, in addition to the screen against Abl SH1, the Ssp-Ssp R7 lariat 
library has also been used against LexA, which resulted in the isolation of two lariats that 
interacted near the autoproteolysis active site of LexA (Barreto et al., 2009). Results from these 
screens suggest that lariats isolated from this library could show a strong bias towards a 
particular epitope of a protein, which is located at or near the active site. Reasons for the bias 
could be that other epitopes may be masked by their interactions with endogenous yeast 
proteins, or the active site of a protein could possess certain epitopes that are more recognizable 
than others. Lariats that interact with less recognizable epitopes may be underrepresented and 
therefore missed during the selection. Increasing the size of a library or using a focused library 
during a screen may help to identify novel lariats that bind to other epitopes.  
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Previous reverse genetic screens have identified a number of constrained peptide 
inhibitors against defined targets, which were shown to be functional in vivo (Chattopadhyay et 
al., 2006; Nouvian et al., 2007; Guida et al., 2008; Brien et al., 2011). No rigorous in vitro 
analyses have been made to characterize their mechanism of action. By performing kinetic 
studies with the synthetic A1 lariat, we showed for the first time that a genetically selected 
lariat can remain functionally active in vitro and can inhibit the enzymatic activity of its target 
with a defined biochemical mechanism. 
5.2. Generation and identification of higher affinity lariats 
5.2.1 Site saturation mutagenesis of the A1 lariat	  	  
Optimizing the “drug like” properties of the lariats, such as affinity, specificity and 
solubility, should increase their potency as inhibitors of protein function. Therefore, we 
explored ways to modify such properties using a simple, robust and cost-effective protocol. In 
phage display and RNA aptamer screens, inhibitors often pass several rounds of selection, and 
therefore emerge with higher affinity (Cortese et al., 1996; Lorsch and Szostak, 1996). Affinity 
maturation of small molecules/synthetic peptides is a laborious process that often requires 
binding-site information, involving synthesis and screening of next-generation combinatorial 
chemical/peptide libraries. In the case of peptide aptamers, lead peptides are subjected to 
random mutagenesis, and tighter-binding variants are selected from mutagenic pools using 
more stringent Y2H reporter genes (Colas et al., 2000). Though this approach can generate 
higher affinity peptide aptamers, the importance of various side-chains on the inhibitor is not 
revealed by using this randomized process. Further, this approach has limitations such as biased 
mutational spectra and low mutation frequency. For example, Colas et al. were able to 
incorporate only two substitutions into a 20-mer Cdk2-interacting peptide aptamer, named 
Pep10, by adopting this approach. The higher affinity variant had a five-fold increase in affinity 
for Cdk2 over Pep10.  
To improve the affinity of the A1 lariat, we first used a random mutagenesis approach. 
We amplified the noose region of the A1 lariat from pIN01-A1 following a mutagenic PCR 
protocol that can cause transitions and transversions by incorporating dPTP (2'-deoxy-P-
nucleoside-5'-triphosphate) and 8-oxo-dGTP (8-oxo-7,8-dihydro-deoxyguanosine-triphosphate) 
into DNA, respectively. We then reintroduced the PCR products into the library vector to 
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construct a second-generation library consisting of 5 million members. Finally, we screened the 
library against Abl SH1 using yeast strains that harbored more stringent LexA operator reporter 
genes with different sensitivities (Colas et al., 2000). However, this approach only gave two 
point variants (ASGWQQLPFEY and ASGWQRLPFGY), which had a less than two-fold 
increase in affinity for Abl SH1 relative to the A1 lariat (data not shown). 
Since the random mutagenesis approach did not produce the desired results, and 
considering that the approach could not generate useful structure-activity relationship data for 
rational drug design, we sought to increase the affinity of the A1 lariat by first determining 
which amino acids are essential for its inhibition. To do this, we used site saturation 
mutagenesis (SSM), a beneficial method that is usually applied to residues in or near the active 
site of proteins during directed evolution (Parikh and Matsumura, 2005; Reetz et al., 2010). By 
employing SSM, we substituted each residue of the A1 lariat against all 20 possible amino 
acids at once, keeping other positions constant. We thus created nine small libraries containing 
20 members each, for nine positions of the A1 lariat, and screened against Abl SH1 using the 
lariat Y2H interaction trap (Barreto et al., 2009). The results of the site-saturation analysis are 
summarized in Figure 5.2.  
We did not get any substitutions at G1, W2, Q3 and L5 positions of the A1 lariat, 
indicating that these amino acids play an important role in contributing to Abl SH1-A1 
interactions. At the fourth position, only 25% of the isolated sequences contain the wt residue 
arginine. Two different mutants, threonine (58%) and serine (17%), bearing hydroxyl side 
chains, account for the rest of the sequences. At the sixth position, there is a strong preference 
for aspartate (75%) over the wt residue proline (12.5%). Serine (12.5%) constitutes the rest of 
the sequences. At the seventh position, tryptophan (70%) often substitutes the wt residue 
phenylalanine (10%), and very few times tyrosine (10%) and histidine (10%) are seen.  
Two positions, E8 and Y9 were fixed in the noose region of the Ssp-Ssp R7 lariat 
library during the primary screen to facilitate lariat formation. As we identified that E8 is not 
required to produce a lariat (Barreto et al., 2009), we randomized glutamate in the secondary 
screen, which gave rise to six new substitutions. Aspartate (19%) and asparagine (19%) are 
preferred at this position over the wt residue (14%). The last position of the lariat (Y9) can be 
substituted with tryptophan (10%) or phenylalanine (10%). However, based on the number of 
hits obtained, wt tyrosine (80%) is preferred at this position.  
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Figure 5.2. Saturation mutagenesis of the A1 lariat: Each position of the A1 lariat was 
saturated with all possible amino acids keeping other positions constant. Nine small libraries 
were thus created for nine positions of the A1 lariat and they were screened against the Abl 
SH1 bait. The prey plasmids were rescued from the hits and sequenced to identify the possible 
amino acid substitutions. The bars in the graph represent the percentage frequency of amino 
acids isolated from saturation mutagenesis screens for each position of the A1 lariat. Wild type 
residues of the A1 lariat are indicated at the bottom of the X-axis. Each amino acid is labeled 
by the one-letter code and standard amino acid colors are used in the graph. 
5.2.2 Affinity maturation of the A1 lariat  
Understanding the significance of various functional groups on the inhibitor scaffold is 
essential to optimize the molecule further. Unfortunately, generation of useful structure-activity 
relationship data,	  once hits are identified from large libraries of compounds, remains a major 
bottleneck in chemical genetics (Kritzer et al., 2009). An advantage of the peptide-based 
approach is that structure-activity relationship data can be generated rapidly and cost-
effectively using mutagenesis.	  	  
We created a series of site-saturation mutants to identify which side chains of the A1 
lariat are important for its function and how less important side chains can be modified to 
improve the properties of the A1 lariat. From the results of the site-saturation analysis, we 
reasoned that the lariats with R4T, P6D, F7W and E8N mutations would bind stronger to Abl 
SH1 relative to the A1 lariat. We thus designed a series of lariat constructs with one or more 
above-mentioned mutations and quantified their interactions with Abl SH1 using the Y2H 
based β-galactosidase assay. We also included F7Y mutation in the assay, as tryptophan (F7W) 
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could lead to a decrease in solubility and specificity of the lariat. The assay results are shown in 
Figure 5.3. 
Among the five point variants tested (R4T, P6D, F7W, F7Y and E8N), three point 
variants (R4T, F7W and E8N) showed ~1.75 fold improvement, the P6D construct showed 
1.25 fold improvement, and the F7Y construct did not show any improvement. Among the nine 
double variants (TG1-TG9) tested, the TG7 construct harboring P6D and E8N substitutions had 
the highest affinity and showed 4.6-fold improvement. In all cases, double variants had higher 
affinities than the corresponding single variants. Among the seven triple variants (TG10-TG16) 
tested, the TG10 construct harboring R4T, P6D and F7W substitutions had the highest affinity 
and showed 7-fold improvement. Notably, the affinity of the TG11 triple variant 
(R4T+P6D+F7Y) was lower than its corresponding double variant (TG1: R4T+P6D). In all 
other cases, triple variants had higher affinities than the corresponding single/double variants. 
The two quadruple variants, TG17 and TG18, with replacements in all the four possible 
positions of the lariat, showed 9-fold and 7-fold improvements, respectively.  
Overall, we designed 18 third generation constructs (TG1-TG18) based on the SSM 
results and assayed them for binding to Abl SH1. We observed an improvement in affinity 
whenever an additional enhancing substitution was added to the A1 lariat.	  Of all the constructs 
tested, the TG17 (R4T+P6D+F7W+E8N) lariat had the highest affinity, followed by the TG18 
(R4T+P6D+F7Y+E8N) and TG10 (R4T+P6D+F7W) lariats. The TG17 lariat showed 9-fold 
improvement in affinity relative to the A1 lariat, whereas the TG18 and TG10 lariats showed 7-
fold improvement. The reasons for this enhancement in affinity could be multiple: (i) new 
hydrogen or ionic bonds could have been formed between the lariat and the target; (ii) the 
hydrophobic contact area at the lariat-target interface could have been increased; (iii) a better 
geometric fit with that of the binding site could have been achieved by the lariat; and (iv) the 
stability of the lariat and/or processing of the intein constructs could have been improved.  
We next checked whether the lariat peptides were amenable to minimization without a 
significant loss in their affinity. Minimization of the lariats would be desirable for downstream 
applications as affinity reagents. We chose to delete the eighth position of the A1, TG17 and 
TG18 lariats, which is less important for Abl SH1-lariat interactions. However, the deletion 
completely abrogated the effects of A1, TG17 and TG18 lariats, indicating that all nine amino 
acids are required for the lariats to be functionally active (Figure 5.3). 
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Figure 5.3. Affinity maturation of the A1 lariat: Lariat constructs with designed mutations 
were analyzed for their interactions with Abl SH1 using Y2H based β-galactosidase assay and 
expressed as Miller units. All interactions were examined three times starting with randomly 
selected independent clones. The bars represent mean ± SD for all experiments.  
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Taken together, we report here a new affinity maturation protocol consisting of two 
steps. In the first step, using SSM, we defined acceptable and tolerable substitutions at each 
position of the A1 lariat. In the second step, we designed specific mutations to the A1 lariat 
based on the SSM results and evolved higher affinity variants. The semi-rational affinity 
maturation protocol used in this study is advantageous over existing protocols in a number of 
ways. The new approach: (i) delineates important residues of the lariats, and generates useful 
structure-activity relationship data for drug design; (ii) explores the sequence space to the 
maximum extent, and minimizes the number of stop codons; (iii) has complete control over the 
position of randomization, and allows subset mutagenesis (e.g. introducing mainly positively 
charged residues); and (iv) is technically simple, robust and economical. The only disadvantage 
of this approach is that it is susceptible to biases arising from: (i) greater incorporation of one 
nucleotide than the other during oligonucleotide synthesis; and (ii) degeneration of triplets 
when they are translated into amino acids (Wong et al., 2006).  
In summary, we show that the lariats are amenable to structure-activity relationship 
studies and optimization by delineating important residues of the A1 lariat and by improving 
the affinity of the A1 lariat, respectively. The ability to easily and rapidly generate useful data 
for rational drug design by mutagenesis should expand the usefulness of lariats as inhibitors of 
protein function. We also show that the affinity maturation protocol used in this study is more 
efficient than random mutagenesis. This new approach is also applicable to peptides isolated 
from phage display and peptide aptamer screens. Comparing the results from various affinity 
maturation experiments may help to answer questions such as how different lariats evolve, how 
many residues remain fixed or change frequently during evolution, do sequences that bind to a 
same kind of epitope eventually converge or diverge during evolution, do sequences evolve to 
resemble any naturally occurring interactors, and what kind of residues determine specificity, 
affinity, stability and processivity of the lariats?  
5.3 Characterization of Abl SH1-interacting lariats	  
5.3.1 Analysis of the binding of peptides to Abl SH1 
 Considering the high conformational flexibility and low intracellular stability of linear 
peptides, genetic selection of constrained peptides is preferred over linear peptides (Horswill 
and Bencovic, 2005). In phage display and peptide aptamer screens, conformational constraint 
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is provided to peptides using disulphide bonds and scaffolding proteins, respectively 
(McConnell et al., 1994; Colas et al., 1996). A major disadvantage of disulphide bond-
constrained peptides is that they are not stable under reducing conditions in cells (McLafferty et 
al., 1993). There are also several limitations in using scaffolding proteins to constrain peptides. 
Their stability, size, expression levels and intrinsic biological activity are of major concern 
(Abedi et al., 1998; Klevenz et al., 2002; Woodman et al., 2005). To overcome many 
limitations associated with scaffold proteins, lariats are constrained by a lactone bond using 
engineered intein domains.  
To highlight the significance of lactone constraint and intein domains used in the lariat 
Y2H system, we cloned the noose regions of the A1, A2, TG17 and TG18 lariats into an 
inactive intein plasmid, which expresses a lariat precursor that does not undergo any steps in 
the intein-mediated cyclization reaction, and a linear peptide plasmid, which expresses a 
peptide whose C-terminus is not constrained by the IN domain. Description and sequences of 
the constructs are shown in Figure 5.4(a) and 5.5(a). We then compared their binding affinities 
for Abl SH1 using the Y2H based β-galactosidase assay. The inactive A1 and A2 peptides 
retained their capacity to interact with Abl SH1 (Figure 5.4b), whereas the inactive TG17 and 
TG18 peptides had an approximately two-fold decrease in affinity for Abl SH1 relative to their 
corresponding lariat constructs (Figure 5.5b). The higher affinity of TG17 and TG18 lariats for 
Abl SH1 relative to their inactive versions indicates that the lariat structure is indeed required 
for these peptides to interact better with the target, highlighting the importance of lactone 
constraint for protein-peptide interactions. However, the lactone constraint may not be required 
for all peptides, particularly lead peptides, to interact with the target.  
As shown in Figure 5.4b and 5.5b, the linear A1, A2, TG17 and TG18 peptides were 
unable to interact with Abl SH1, confirming the importance of intein domains used in the Y2H 
system. One reason that these linear peptides do not recognize the target may be their short 
half-lives in cells. The linear constructs used in our assays contain a free C-terminus, which 
may be open to degradation by cellular exoproteases (Horswill and Bencovic, 2005). Linear 
peptides may also be susceptible to proteosomal degradation. Previous studies have showed 
that only 5% of random unconstrained peptides fold into structures (Davidson and Sauer, 
1994), and unstructured peptides are degraded by proteosomes because they are recognized as 
misfolded proteins (Baumeister and Lupas, 1997; Groll et al., 1997). Apart from their low
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Figure 5.4. Y2H constructs and analysis: (a) Sequences of A1 and A2 lariat, inactive and 
linear peptide constructs. The lariats contain an Asn to Ala mutation at position IC-1, which 
inhibits Asn side chain cyclization reaction and stops the reaction at the lariat intermediate. 
This mutation prevents the formation of a lactone cyclized peptide. The inactive constructs 
contain the same mutations as the lariat and a Cys to Ala mutation at position IN+1. The Cys to 
Ala mutation blocks the N to S acyl shift and only produces a lariat precursor. The linear 
peptides contain a stop codon at the IN+1 position. (b) Y2H analysis of the interaction of Abl 
SH1 with the above mentioned constructs and the pIN01 plasmid. pIN01 is a control plasmid 
that expresses an inactive intein with a CGPC peptide noose. The interactions were quantified 
using Y2H based β-galactosidase assay and expressed as Miller units. All interactions were 
examined three times starting with randomly selected independent clones. The bars represent 
mean ± SD for all experiments. 
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Figure 5.5. Y2H constructs and analysis: (a) Sequences of TG17 and TG18 lariat, inactive 
and linear peptide constructs. The lariats contain an Asn to Ala mutation at position IC-1, which 
inhibits Asn side chain cyclization reaction and stops the reaction at the lariat intermediate. 
This mutation prevents the formation of a lactone cyclized peptide. The inactive constructs 
contain the same mutations as the lariat and a Cys to Ala mutation at position IN+1. The Cys to 
Ala mutation blocks the N to S acyl shift and only produces a lariat precursor. The linear 
peptides contain a stop codon at the IN+1 position. (b) Y2H analysis of the interaction of Abl 
SH1 with the above mentioned constructs and the pIN01 plasmid. pIN01 is a control plasmid 
that expresses an inactive intein with a CGPC peptide noose. The interactions were quantified 
using Y2H based β-galactosidase assay and expressed as Miller units. All interactions were 
examined three times starting with randomly selected independent clones. The bars represent 
mean ± SD for all experiments. 
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intracellular stability, linear peptides do not possess a conformational constraint that may be 
needed to recognize the target. In the case of inactive peptides, though the lactone constraint is 
absent, the peptide noose is still flanked by intein domains, which would impose a 
conformational constraint, and protect the noose region from exoproteases. 
5.3.2 In vitro activity of the higher affinity peptides 
 To quantitate the inhibitory activity of the TG17 and TG18 lariats in vitro, we used the 
continuous spectroscopic kinase assay (Boerner et al., 1995). Truncated versions of the lariats 
were synthesized as mentioned in section 5.1.3 and tested against purified Abl kinase. Dose 
response curves showed the Ki of synthetic TG17 (A-[SGWQTLDWNY]) and TG18 (A-
[SGWQTLDYNY]) lariats to be 804 nM and 2.41 µM, respectively, establishing a strong 
inhibition of Abl kinase activity (Figure 5.6). In agreement with Y2H results, the TG17 lariat 
exhibited a stronger efficacy than the TG18 lariat.   
 To examine the effect of lariat structure on Abl kinase inhibition, we evaluated the 
inhibitory activity of linear peptides corresponding to the TG17 and TG18 lariats. Dose 
response curves showed the Ki of synthetic TG17 (ASGWQTLDWNY) and TG18 
(ASGWQTLDYNY) linear peptides to be 5.76 µM and 13.28 µM, respectively, indicating that 
the linear versions are about five to seven times less efficient than the lariat peptides at 
inhibiting the Abl kinase activity (Figure 5.6). This decrease in the inhibitory activity suggests 
that the linear peptides may not be adopting the optimal conformation needed to strongly 
interact with the target.  
 Our data confirm previous reports describing that genetically selected peptides show a 
decrease in their efficiency when assayed without a constraint. A synthetic linear peptide 
corresponding to the variable region of a Cdk2-interacting peptide aptamer showed a ~ 1000 
fold decrease in its efficiency at inhibiting the kinase activity of Cdk2 (Cohen et al., 1998). In 
the case of a peptide aptamer that binds to ubiquitin ligase mouse double minute 2-protein 
(MDM2), the unconstrained peptide interacted ~ two fold less strongly with MDM2 than the 
constrained peptide (Brown et al., 2009). These results support the idea that the variable region 
of peptides is sufficient for activity and that the conformational constraint imposed on the 
variable region allows for a high-affinity interaction by lowering the entropic cost of binding. 
In contrast, there are some cases in which free peptides corresponding to the variable region of
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Figure 5.6. In vitro activity of higher affinity peptides: Recombinant c-Abl SH3-SH2-kinase 
was mixed with different concentrations of the synthetic higher affinity peptides, and kinase 
assays were performed using Abltide as a substrate.  The values from individual samples were 
analyzed and plotted as a function of inhibitor concentration to determine the IC50 values of the 
higher affinity peptides. Inhibitory constants (Ki) were calculated from the IC50 values using 
the Cheng-Prusoff relationship (see methods). 	  (a) Dose-dependent inhibitory activity of TG17 
lariat and linear peptides. (b) Dose-dependent inhibitory activity of TG18 lariat and linear 
peptides. (c) IC50 and Ki values of the higher affinity peptides derived from dose-response 
curves.  
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peptide aptamers retained their capacity to bind/inhibit the target (Schmidt et al., 2002; Martel 
et al., 2006; Nouvion et al., 2007), suggesting that the linear versions of genetically selected 
constrained peptides could also adopt a functional structure without a constraint.  
5.3.3 In vivo activity of the lariats 
 Having demonstrated direct biochemical inhibition of Abl kinase activity, we proceeded 
to evaluate the in vivo inhibition of the Bcr-Abl kinase activity by the lariats. To do this, we 
subcloned the intein peptides into the murine stem cell virus vector and transiently transfected 
them into K562 cells that ectopically express the wild-type p210 Bcr-Abl oncoprotein. First, we 
confirmed the expression and processing of intein constructs using Western analysis with an 
antibody against the C-terminal FLAG tag. The A1 lariat plasmid released the FLAG tagged IN 
domain, confirming the processing of inteins and production of the lariat (Figure 5.7a). Next, 
we determined the viability of the K562 cells by trypan blue exclusion to examine whether the 
lariats act against Bcr-Abl expressing cells. Expression of the lariats A1, TG17 and TG18 for 
24 hours reduced the cell survival to 73%, 60% and 73%, respectively, relative to untreated 
cells that had 94% survival. Expression of the intein machinery alone reduced the cell survival 
to 86% relative to the untreated cells (Figure 5.7b). Finally, to confirm the inhibition of Bcr-
Abl kinase activity by the lariats, we tested the effect of intracellular expression of the lariats 
on the phosphorylation status of Hck, a Src family kinase, which is constituently activated by 
Bcr-Abl for CML induction (Klejman et al., 2002). As shown in Figure 5.7c, there was a 
substantial inhibition of Hck phosphorylation in the cells transfected with lariats, establishing 
that the effects of the lariats on the viablity of the cells are indeed mediated via inhibition of 
Bcr-Abl kinase activity and are not because of off-target effects. Together, these in vivo studies 
clearly illustrate the potential of lariats as intracellular inhibitors of endogenous Bcr-Abl 
dependent signaling events. 
  Numerous studies have established the utility of various trans dominant agents such as 
small molecules, antibodies, synthetic peptides, peptide aptamers and monobodies in the 
manipulation of intracellular networks for research and therapeutic purposes (Barreto, 2010). 
We report here the first functional expression of lariats within mammalian cells, and 
demonstrate that lariats isolated and characterized using Y2H assays can be used as 
intracellular inhibitors. The ability of lariats to inhibit specific proteins, both in vitro and in
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Figure 5.7. In vivo activity of the lariats: (a) Intein processing in K562 cells transfected with 
A1 lariat plasmid. Intein processing was detected by Western analysis using an anti-FLAG 
antibody. Calculated molecular weights of FLAG-tagged unprocessed intein construct and 
FLAG-tagged Ssp-IN domain are 23.89 kDa and 14.98 kDa, respectively. (b) Effect of lariats 
on viability of K562 cells. Cells were transfected with lariat or intein plasmids and viability 
was assessed by tryphan blue exclusion after 24 hours. Intein plasmid has a CGPC peptide 
noose flanked by intein domains. Transfection efficiency was determined to be ~75% for all the 
plasmids by flow cytometry (not shown). (c) Effect of lariats and imatinib on the 
phosphorylation status of Hck in K562 cells. Cells treated with 1 µM imatinib or transfected 
with lariat or intein plasmids were lysed after 24 hours of treatment/transfection. Lysates were 
subjected to immunoblotting for detection of Hck phosphorylated at Tyr411 and total Hck. 
 vivo, suggests that they can be used as chemical genetic tools to study biochemical pathways, 
regulatory networks and cellular processes. More specifically, the anti-Abl lariats should prove 
valuable in the dissection of Bcr-Abl pathways, and to further investigate leukemogenesis. One 
major advantage in employing lariats for in vivo studies is that they can be delivered into cells 
using different approaches. In this study, we have used a retroviral vector to express lariats 
within cells. This method is valuable to control the expression of peptides in transfected cells, 
and to deliver peptides into target cells through viral infection. It is also possible to deliver 
lariats into cells with the help of protein transduction domains (Buerger and Groner, 2003) and 
cell-penetrating peptides (Saar et al., 2005).  
5.3.4 Resistant mutation profile of the higher affinity lariats 
 In order to compare the affinity of the lariats TG17 and TG18 for drug resistant Abl 
kinase mutants, we performed site directed mutagenesis to create a series of mutant Abl SH1 
baits and assayed them against the lariats using the Y2H based β-galactosidase assay. The 
lariats TG17 and TG18 interacted with all the Abl SH1 mutant baits, but with a lower affinity 
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compared to that of WT bait. The only exception to this is the H396P Abl SH1 bait for which 
the lariats displayed a ~2.5 fold higher affinity than for WT Abl SH1 (Figure 5.8).  
 We extrapolated the finding that the lariats bind to the catalytic cleft to reason out why 
the lariats had a change in affinity for drug resistant mutants. Thr315 is positioned on the 
surface of the ATP site, and an Ile mutation in that position can confer drug resistance via three 
different ways. The mutation: (i) leads to the loss of a hydrogen bond between Thr315 and the 
inhibitor; (ii) blocks the entry of the inhibitor into the back cleft and (iii) promotes 
conformational dynamics in the kinase domain (Azam et al., 2008). Mutation Y253F causes 
drug resistance by altering the distorted conformation of the phosphate-binding loop of the 
kinase. In addition, this mutation leads to the loss of direct binding between the drug and the 
side chain of tyrosine (Krishnamurthy and Maly, 2010). The decrease in affinity of the lariats 
for the T315I and Y253F mutants could be due to a change in the original conformation of the 
kinase and/or loss of bonded/steric interactions between the lariats and the target. 
Mutation E355G is present in the catalytic loop of the kinase and confers drug 
resistance by indirectly altering the hydrophobic core of the catalytic cleft (Cowan-Jacob et al., 
2004). The decrease in affinity of the lariats for the E355G mutant could be due to a change in 
the original shape/flexibility of the catalytic cleft required for lariat binding.  
 Mutations H396P and H396R are located in the activation loop of the kinase and cause 
resistance to drugs like imatinib and nilotinib by altering the Abl/c-Kit–like inactive 
conformation of the kinase, which is required for imatinib/nilotinib binding (Cowan-Jacob et 
al., 2004). The H396R mutation could favor the formation of the inactive Src/Cdk–like 
conformation (Bharathikumar and Geyer, unpublished work). As the affinity of the lariats is 
decreased for H396R Abl SH1 relative to WT Abl SH1, it appears that the lariats do not prefer 
the inactive Src/Cdk–like conformation of the kinase for binding.   
Structural studies have shown that the H396P mutation causes Abl to adopt the active 
conformation from the original Abl/c-Kit like conformation (Young et al., 2006). The lariats 
interacted stronger with H396P Abl SH1 than WT Abl SH1, indicating that the lariats prefer the 
active conformation of the kinase for binding. This conformational preference could be a 
consequence of the lariats having been isolated using a yeast-based screen in which the kinases 
are highly active. In fact, Western analysis using a phosphospecific antibody that recognizes 
Abl phosphorylated at Tyr412 revealed that the activation loop of the LexA DBD-Abl SH1
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Figure 5.8. Resistant mutation profile of TG17 and TG18 lariats: (a) Y2H analysis of the 
interactions between Abl SH1 mutants and the lariats with two different selective media: (i) a 
less stringent synthetic galactose His- Trp- Leu- media (SG H-W-L-), which selects for the 
activation of LEU2 reporter gene, and (ii) a more stringent synthetic galactose His- Trp- Leu- 
Ade- Xgal+ media (SG H-W-L-A-Xgal+), which selects for the activation of LEU2, ADE2, and 
LacZ reporter genes. SD H-W- represents yeast grown on nonselective synthetic dextrose His- 
Trp- media. (b) Interactions between Abl SH1 mutants and the lariats were quantified using 
Y2H based β-galactosidase assay and expressed as Miller units. All interactions were examined 
three times starting with randomly selected independent clones. The bars represent mean ± SD 
for all experiments. LexA bait was included as a negative control. 
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construct is predominantly phosphorylated in yeast (data not shown). Targeting the active 
conformation has at least two advantages: (i) the diseased state of the kinase is present in the 
active form; and (ii) the active conformation-specific inhibitors are only susceptible to 
mutations that directly impair drug binding. In contrast, inactive conformation-specific 
inhibitors are additionally susceptible to mutations that destabilize the specific inactive form 
and promote kinase activation (Johnson, 2009). Also, it is beneficial to further characterize 
active conformation-specific inhibitors because druggable allosteric sites of Abl kinase in its 
active form have not yet been analyzed, and such analysis could gain more insights into the 
design of highly selective drugs. 
5.3.5 Selectivity profile of the TG17 lariat 
 In order to evaluate the kinase selectivity of higher affinity lariats, we assayed a panel of 
200 kinases in the presence and absence of the synthetic TG17 lariat using an ATP site-
dependent in vitro competition-binding assay (KinexTM Protein Kinase Microarray-200). Using 
this approach, the lariat was incubated with a biotinylated ATP probe on the protein kinase 
microarray. If the lariat binds to the kinase and directly or indirectly occludes the ATP binding 
pocket, then fewer probes can covalently bind to the ATP site. If the lariat does not bind to the 
kinase, there is no reduction in the binding of probes to the ATP site. The results were read out 
by quantifying the amount of ATP probe bound to the kinases using fluorescently labeled 
streptavidin conjugates.  
 The analysis revealed that the TG17 lariat possessed a selective profile, interacting with 
only 19 kinases among the KinexTM 200 diverse kinases panel at a concentration of 10 µM 
(Table 5.1). Kinases that had a relative binding score of less than 50% of the DMSO control 
were predicted as non-binders. The lariat had a slightly higher affinity for few off-targets in the 
panel than for the intended target. Few off-targets like Jak2 (Xie et al., 2001), Mek1/2 
(Steelman et al., 2004) and Insulin-like growth factor 1 receptor (Lakshmikuttyamma et al., 
2008), were indeed directly or indirectly activated by Bcr-Abl during the progression of the 
disease. Most notably, the lariat did not recognize any of the Src family kinases, which share a 
high structural similarity with Abl kinase in their active conformation (Young et al., 2006). In 
contrast, dasatinib binds to Abl kinase as well as to Src family kinases (Shah et al., 2004). A 
comprehensive analysis of selectivity using a competition-binding assay (Ambit Biosciences) 
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revealed that dasatinib interacted with 88 out of 317 kinases at 3 µM concentration (Karaman et 
al., 2008). The discrimination of Src family kinases by the TG17 lariat strongly suggests that 
the inhibitor might occupy less-conserved binding pockets in the kinase catalytic cleft. 
Table 5.1: Kinome interaction profile of TG17 lariat at 10 µM concentration 
Protein kinase Group Family Fold change in affinity 
relative to ABL1 
Mylk2 CAMK Mylk 1.77 
Plk1 Other Plk 1.64 
CK2a1 Other CK2 1.41 
Cdk7 CMGC Cdk 1.34 
Aurora C Other Aurora 1.21 
Cdk5/P25 CMGC Cdk 1.16 
IGF1R TK InsR 1.14 
VEGFR1 TK VEGFR 1.11 
Taok1 STE STE20 1.06 
CAMK2b CAMK CAMK3 1.04 
Txk TK TEC 1.03 
Mek1 STE STE7 1.03 
Abl1  TK Abl 1.00 
Mst4 STE STE20 0.99 
Rsk1 AGC Rsk 0.93 
Cdk6/CyclinD3 CMGC Cdk 0.92 
Cdk6/CyclinD1 CMGC Cdk 0.91 
Jak2 TK Jak 0.90 
Mek2 STE STE7 0.87 
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6. Conclusions and Future Directions 
The first step in the identification and characterization of new binding pockets in a 
therapeutically validated target is to screen for a new class of inhibitors that could potentially 
recognize novel druggable surfaces on the target. In an attempt to identify new allosteric drug 
binding pockets in the kinase catalytic cleft, we isolated lariat peptide inhibitors against Abl 
kinase, a drug target important in chronic myeloid leukemia and other disorders. Using in vitro 
kinetic and binding assays, we showed that a synthetic lariat, named A1, binds to the catalytic 
cleft that lies between the N- and C- lobes of the kinase catalytic domain, but not to the 
substrate peptide or the myristate binding region. To obtain tighter-binding variants of the A1 
lariat, we developed an affinity maturation protocol consisting of two steps. In the first step, we 
defined acceptable and tolerable substitutions at each position of the A1 lariat using site-
saturation mutagenesis (SSM). In the second step, we designed specific mutations to the A1 
lariat based on the SSM results and evolved higher affinity variants. Synthetic and recombinant 
higher affinity lariats exhibited a strong inhibition of Abl kinase activity in vitro and Bcr-Abl 
kinase activity in vivo, respectively.  
Finally, we evaluated the resistant mutation and selectivity profiles of the higher affinity 
lariats. While evaluating the resistant mutation profiles, we identified that the lariats bind 
specifically to the active state of kinase and possess the ability to differentiate closely related 
conformations of the kinase. By profiling a higher affinity lariat, named TG17, against a panel 
of 200 kinases, we identified that the lariat has a selective profile interacting with only 19 
kinases. Selectivity analysis also indicated that the lariats do not recognize Src family kinases, 
which share a high structural similarity with Abl kinase in their active conformation. The 
discrimination of Hck, a Src family kinase, by anti Abl lariats was also confirmed by the lariat 
Y2H assay. Further, we were able to obtain lariats against Hck by designing mutations to the 
anti Abl lariats (Appendix 1). Once the structure of Abl kinase in complex with a lariat is 
solved, the information that we obtained from various mutagenesis screens could be useful to 
improve or to change the kinase selectivity profiles of small molecules. 
Preliminary modeling studies showed that the TG17 lariat do not bind to the adenine-
binding pocket (A-pocket) of Abl kinase. The lariat recognizes novel surfaces that lie adjacent 
to the A-pocket, while the catalytic cleft is in the active conformation. The lariat binds to the 
target through an unique entrance at the αC side (Appendices 2 and 3).   
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From the methodology perspective, we have demonstrated a number of things in this 
project. First, we show that a genetically selected lariat can remain functionally active in vitro 
and can inhibit the enzymatic activity of its target with a defined biochemical mechanism. 
Second, we confirm the processing of intein constructs and formation of the lariat in 
mammalian cells, and provide evidence that the lariats can function as intracellular inhibitors of 
endogenous signaling pathways and protein-protein interactions. Third, we demonstrate the 
potential of the lariat peptide approach in generating conformer specific affinity reagents. 
Taken together, we clearly illustrate that the lariats are powerful chemical genetic tools for 
performing reverse analysis of protein function. 
Currently, we are performing biophysical experiments to confirm that the lariats do 
recognize allosteric sites in the kinase catalytic cleft. Once the allosteric recognition is 
confirmed, we would identify small molecules that disrupt Abl kinase-lariat interactions using 
peptide displacement screens. We are also involved in obtaining a NMR structure of the lariat, 
and a crystal structure of Abl kinase in complex with the lariat. These structures would provide 
information for the rational design of small molecules with improved properties, and for 
grafting the novel pharmacophores of the lariat onto existing small molecules using 
peptidomimetics. In addition to biophysical and structural studies, experiments to illustrate the 
power of lariat peptide technology in studying animal models of human disease are currently 
underway in our laboratory.   
 
 
 
 
 
 
 
 
 
 
 
 
	   68	  
7. References 
Adrian, F.J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., 
Manley, P., et al. (2006). Allosteric inhibitors of Bcr-Abl dependent cell proliferation. Nat. 
Chem. Biol. 2, 95-102. 
Abedi, M.R., Caponigro, G., and Kamb, A. (1998). Green fluorescent protein as a scaffold for 
intracellular presentation of peptides. Nucleic Acids Res. 26, 623-630. 
Advani, A.S., and Pendergast, A.M. (2002). Bcr-Abl variants: biological and clinical aspects. 
Leuk. Res. 26, 713-720. 
Ausubel, F.M., Brent, R., and Kingston, R.E. (1988). Current Protocols in Molecular Biology 
(New York: John Wiley & Sons). 
Ausubel, F.M., Brent, R., Kingston R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, 
K. (1997). Current Protocols in Molecular Biology (New York: John Wiley & Sons). 
Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J., and Daley, G.Q. (2008). Activation of 
tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109-
1118. 
Bardou, C., Borie, C., Bickle, M., Rudkin, B.B., and Colas, P. (2009). Peptide aptamers for 
small molecule drug discovery. Methods Mol. Biol. 535, 373-388. 
Barker, S.C., Kassel, D.B., Weigl, D., Huang, X., Luther, M.A., and Knight, W.B. (1995). 
Characterization of pp60c-Src tyrosine kinase activities using a continuous assay: 
autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 
34, 14843-14851. 
Barreto, K. (2010). A genetic screen to isolate “lariat” peptide inhibitors of protein function. 
Doctoral dissertation, University of Saskatchewan, Saskatoon.  
Barreto, K., Bharathikumar, V.M., Ricardo, A., DeCoteau, J.F., Luo, Y., and Geyer, C.R. 
(2009). A genetic screen for isolating "lariat" peptide inhibitors of protein function. Chem. 
Biol. 16, 1148-1157. 
Baumeister, W., and Lupas, A. (1997). The proteasome. Curr. Opin. Struct. Biol. 7, 273-278. 
Bishop, A.C. (2004). A hot spot for protein kinase inhibitor sensitivity. Chem. Biol. 11, 587-
589. 
Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature 411, 355-365. 
Boerner, R.J., Barker, S.C., and Knight, W.B. (1995). Kinetic mechanisms of the forward and 
reverse pp60c-Src tyrosine kinase reactions. Biochemistry 34, 16419-16423. 
Bogoyevitch, M.A., Barr, R.K., and Ketterman, A.J. (2005). Peptide inhibitors of protein 
kinases-discovery, characterisation and use. Biochim. Biophys. Acta 1754, 79-99. 
	   69	  
Borghouts, C., and Weiss, A. (2009). Production and purification of monomeric recombinant 
peptide aptamers: requirements for efficient intracellular uptake and target inhibition. In 
Peptides as drugs, B. Groner, ed. (Weinheim, Germany: Wiley-VCH), pp.145-186. 
Brenke, R., Kozakov, D., Chuang, G.Y., Beglov, D., Hall, D., Landon, M.R., Mattos, C., and 
Vajda, S. (2009). Fragment-based identification of druggable 'hot spots' of proteins using 
Fourier domain correlation techniques. Bioinformatics 25, 621-627. 
Brien, G., Debaud, A.L., Bickle, M., Trescol-Biemont, M.C., Moncorge, O., Colas, P., and 
Bonnefoy-Berard, N. (2011). Characterization of peptide aptamers targeting Bfl-1 anti-
apoptotic protein. Biochemistry 50, 5120-5129. 
Brown, C.J., Dastidar, S.G., See, H.Y., Coomber, D.W., Ortiz-Lombardia, M., Verma, C., and 
Lane, D.P. (2010). Rational design and biophysical characterization of thioredoxin-based 
aptamers: insights into peptide grafting. J. Mol. Biol. 395, 871-883. 
Brown, N.R., Noble, M.E., Endicott, J.A., and Johnson, L.N. (1999). The structural basis for 
specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell. Biol. 
1, 438-443. 
Buerger, C., and Groner, B. (2003). Bifunctional recombinant proteins in cancer therapy: cell 
penetrating peptide aptamers as inhibitors of growth factor signaling. J. Cancer Res. Clin. 
Oncol. 129, 669-675. 
Buerger, C., Nagel-Wolfrum, K., Kunz, C., Wittig, I., Butz, K., Hoppe-Seyler, F., and Groner, 
B. (2003). Sequence-specific peptide aptamers, interacting with the intracellular domain of the 
epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of 
tumor cells. J. Biol. Chem. 278, 37610-37621. 
Cattaneo, A., and Biocca, S. (1999). The selection of intracellular antibodies. Trends 
Biotechnol. 17, 115-121. 
Chattopadhyay, A., Tate, S.A., Beswick, R.W., Wagner, S.D., and Ko Ferrigno, P. (2006). A 
peptide aptamer to antagonize BCL-6 function. Oncogene 25, 2223-2233. 
Cherry, M., and Williams, D.H. (2004). Recent kinase and kinase inhibitor X-ray structures: 
mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11, 663-673. 
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., Jr., and 
Leahy, D.J. (2003). Structure of the extracellular region of HER2 alone and in complex with 
the Herceptin Fab. Nature 421, 756-760. 
Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., 
Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate 
kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233. 
Cohen, B.A., Colas, P., and Brent, R. (1998). An artificial cell-cycle inhibitor isolated from a 
combinatorial library. Proc. Natl. Acad. Sci. U. S. A. 95, 14272-14277. 
Cohen, M.S., Zhang, C., Shokat, K.M., and Taunton, J. (2005). Structural bioinformatics-based 
	   70	  
design of selective, irreversible kinase inhibitors. Science 308, 1318-1321. 
Cohen, P. (2002). Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. 
Drug Discov. 1, 309-315. 
Colas, P., Cohen, B., Jessen, T., Grishina, I., McCoy, J., and Brent, R. (1996). Genetic selection 
of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380, 548-550. 
Colas, P., Cohen, B., Ko Ferrigno, P., Silver, P.A., and Brent, R. (2000). Targeted modification 
and transportation of cellular proteins. Proc. Natl. Acad. Sci. U. S. A. 97, 13720-13725. 
Coleman, R.G., Salzberg, A.C., and Cheng, A.C. (2006). Structure based identification of small 
molecule binding sites using a free energy model. J. Chem. Inf. Model. 46, 2631-2637. 
Cortese, R., Monaci, P., Luzzago, A., Santini, C., Bartoli, F., Cortese, I., Fortugno, P., Galfre, 
G., Nicosia, A., and Felici, F. (1996). Selection of biologically active peptides by phage display 
of random peptide libraries. Curr. Opin. Biotechnol. 7, 616-621. 
Cowan-Jacob, S.W., Guez, V., Fendrich, G., Griffin, J.D., Fabbro, D., Furet, P., Liebetanz, J., 
Mestan, J., and Manley, P.W. (2004). Imatinib (STI571) resistance in chronic myelogenous 
leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. 
Mini Rev. Med. Chem. 4, 285-299. 
Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous 
leukemia in mice by the P210 Bcr/Abl gene of the Philadelphia chromosome. Science 247, 
824-830. 
Davidson, A.R., and Sauer, R.T. (1994). Folded proteins occur frequently in libraries of 
random amino acid sequences. Proc. Natl. Acad. Sci. U. S. A. 91, 2146-2150. 
Davis, R.J. (1993). The mitogen-activated protein kinase signal transduction pathway. J. Biol. 
Chem. 268, 14553-14556. 
Dong, Q., Dougan, D.R., Gong, X., Halkowycz, P., Jin, B., Kanouni, T., O'Connell, S.M., 
Scorah, N., Shi, L., Wallace, M.B., et al. (2011). Discovery of TAK-733, a potent and selective 
MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett. 21, 1315-
1319. 
Dong, X., Stothard, P., Forsythe, I.J., and Wishart, D.S. (2004). PlasMapper: a web server for 
drawing and auto-annotating plasmid maps. Nucleic Acids Res. 32, W660-664. 
Elbing, K., and Brent, R. (2002). Current Protocols in Molecular Biology (New York: John 
Wiley & Sons). 
Eldar-Finkelman, H., and Eisenstein, M. (2009). Peptide inhibitors targeting protein kinases. 
Curr. Pharm. Des. 15, 2463-2470. 
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S.W., Fendrich, G., Liebetanz, J., 
Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002). Protein kinases as targets for 
anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93, 79-98. 
	   71	  
Faivre, S., Kroemer, G., and Raymond, E. (2006). Current development of mTOR inhibitors as 
anticancer agents. Nat. Rev. Drug Discov. 5, 671-688. 
Fischmann, T.O., Smith, C.K., Mayhood, T.W., Myers, J.E., Reichert, P., Mannarino, A., Carr, 
D., Zhu, H., Wong, J., Yang, R.S., et al. (2009). Crystal structures of MEK1 binary and ternary 
complexes with nucleotides and inhibitors. Biochemistry 48, 2661-2674. 
Force, T., and Kolaja, K.L. (2011). Cardiotoxicity of kinase inhibitors: the prediction and 
translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126. 
Fuh, G., Wu, P., Liang, W.C., Ultsch, M., Lee, C.V., Moffat, B., and Wiesmann, C. (2006). 
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and 
comparison with the Avastin Fab. J. Biol. Chem. 281, 6625-6631. 
Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and 
Stratton, M.R. (2004). A census of human cancer genes. Nat. Rev. Cancer 4, 177-183. 
Geiger, T.R., and Peeper, D.S. (2007). Critical role for TrkB kinase function in anoikis 
suppression, tumorigenesis, and metastasis. Cancer Res. 67, 6221-6229. 
Geyer, C.R., and Brent, R. (2000). Selection of genetic agents from random peptide aptamer 
expression libraries. Methods Enzymol. 328, 171-208. 
Gietz, R.D., and Schiestl, R.H. (2007). Frozen competent yeast cells that can be transformed 
with high efficiency using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 1-4. 
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., Davies, H., 
Teague, J., Butler, A., Stevens, C., et al. (2007). Patterns of somatic mutation in human cancer 
genomes. Nature 446, 153-158. 
Grimminger, F., Schermuly, R.T., and Ghofrani, H.A. (2010). Targeting non-malignant 
disorders with tyrosine kinase inhibitors. Nat. Rev. Drug Discov. 9, 956-970. 
Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, H.D., and Huber, R. (1997). 
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386, 463-471. 
Guida, E., Bisso, A., Fenollar-Ferrer, C., Napoli, M., Anselmi, C., Girardini, J.E., Carloni, P., 
and Del Sal, G. (2008). Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. 
Cancer Res. 68, 6550-6558. 
Gumireddy, K., Baker, S.J., Cosenza, S.C., John, P., Kang, A.D., Robell, K.A., Reddy, M.V., 
and Reddy, E.P. (2005). A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib 
resistance. Proc. Natl. Acad. Sci. U. S. A. 102, 1992-1997. 
Hanks, S.K., and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification. Faseb J. 9, 576-596. 
Hantschel, O., and Superti-Furga, G. (2004). Regulation of the c-Abl and Bcr-Abl tyrosine 
kinases. Nat. Rev. Mol. Cell. Biol. 5, 33-44. 
 
	   72	  
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and Superti-
Furga, G. (2003). A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857. 
Hardy, J.A., and Wells, J.A. (2004). Searching for new allosteric sites in enzymes. Curr. Opin. 
Struct. Biol. 14, 706-715. 
Hoffman, C.S., and Winston, F. (1987). A ten-minute DNA preparation from yeast efficiently 
releases autonomous plasmids for transformation of Escherichia coli. Gene 57, 267-272. 
Hoppe-Seyler, F., Crnkovic-Mertens, I., Denk, C., Fitscher, B.A., Klevenz, B., Tomai, E., and 
Butz, K. (2001). Peptide aptamers: new tools to study protein interactions. J. Steroid Biochem. 
Mol. Biol. 78, 105-111. 
Horswill, A.R., and Benkovic, S.J. (2005). Cyclic peptides, a chemical genetics tool for 
biologists. Cell Cycle 4, 552-555. 
Hu, Y., Fang, X., Dunham, S.M., Prada, C., Stachowiak, E.K., and Stachowiak, M.K. (2004). 
90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 
(FGFR1): role in FGFR1 signaling. J. Biol. Chem. 279, 29325-29335. 
Hua, S.B., Qiu, M., Chan, E., Zhu, L., and Luo, Y. (1997). Minimum length of sequence 
homology required for in vivo cloning by homologous recombination in yeast. Plasmid 38, 91-
96. 
Hubbard, S.R., and Till, J.H. (2000). Protein tyrosine kinase structure and function. Annu. Rev. 
Biochem. 69, 373-398. 
Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell 109, 
275-282. 
Isshiki, Y., Kohchi, Y., Iikura, H., Matsubara, Y., Asoh, K., Murata, T., Kohchi, M., 
Mizuguchi, E., Tsujii, S., Hattori, K., et al. (2011). Design and synthesis of novel allosteric 
MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg. Med. Chem. Lett. 
21, 1795-1801. 
Ivetac, A., and McCammon, J.A. (2010). Mapping the druggable allosteric space of G-protein 
coupled receptors: a fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 76, 
201-217. 
Jatiani, S.S., Cosenza, S.C., Reddy, M.V., Ha, J.H., Baker, S.J., Samanta, A.K., Olnes, M.J., 
Pfannes, L., Sloand, E.M., Arlinghaus, R.B., et al. (2010). A non-ATP competitive dual 
inhibitor of JAK2 and BCR-ABL Kinases: elucidation of a novel therapeutic spectrum based 
on substrate competitive inhibition. Genes Cancer 1, 331-345. 
Johnson, L.N. (2009). Protein kinase inhibitors: contributions from structure to clinical 
compounds. Q. Rev. Biophys. 42, 1-40. 
Johnson, L.N., and Lewis, R.J. (2001). Structural basis for control by phosphorylation. Chem. 
Rev. 101, 2209-2242. 
	   73	  
Kaidanovich-Beilin, O., and Eldar-Finkelman, H. (2006). Peptides targeting protein kinases: 
strategies and implications. Physiology (Bethesda) 21, 411-418. 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., 
Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). A quantitative analysis of kinase 
inhibitor selectivity. Nat. Biotechnol. 26, 127-132. 
Kerbel, R.S. (2008). Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049. 
Klejman, A., Schreiner, S.J., Nieborowska-Skorska, M., Slupianek, A., Wilson, M., Smithgall, 
T.E., and Skorski, T. (2002). The Src family kinase Hck couples BCR/ABL to STAT5 
activation in myeloid leukemia cells. Embo J. 21, 5766-5774. 
Klevenz, B., Butz, K., and Hoppe-Seyler, F. (2002). Peptide aptamers: exchange of the 
thioredoxin-A scaffold by alternative platform proteins and its influence on target protein 
binding. Cell Mol. Life Sci. 59, 1993-1998. 
Koivunen, E., Wang, B., and Ruoslahti, E. (1994). Isolation of a highly specific ligand for the 
alpha 5 beta 1 integrin from a phage display library. J. Cell. Biol. 124, 373-380. 
Kolonin, M.G., and Finley, R.L., Jr. (1998). Targeting cyclin-dependent kinases in Drosophila 
with peptide aptamers. Proc. Natl. Acad. Sci. U. S. A. 95, 14266-14271. 
Kontopidis, G., McInnes, C., Pandalaneni, S.R., McNae, I., Gibson, D., Mezna, M., Thomas, 
M., Wood, G., Wang, S., Walkinshaw, M.D., et al. (2006). Differential binding of inhibitors to 
active and inactive CDK2 provides insights for drug design. Chem. Biol. 13, 201-211. 
Krishnamurty, R., and Maly, D.J. (2010). Biochemical mechanisms of resistance to small-
molecule protein kinase inhibitors. ACS Chem. Biol. 5, 121-138. 
Kritzer, J.A., Hamamichi, S., McCaffery, J.M., Santagata, S., Naumann, T.A., Caldwell, K.A., 
Caldwell, G.A., and Lindquist, S. (2009). Rapid selection of cyclic peptides that reduce alpha-
synuclein toxicity in yeast and animal models. Nat. Chem. Biol. 5, 655-663. 
Kunz, C., Borghouts, C., Buerger, C., and Groner, B. (2006). Peptide aptamers with binding 
specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and 
sensitize breast cancer cells to Taxol. Mol. Cancer Res. 4, 983-998. 
Kwak, E.L., Sordella, R., Bell, D.W., Godin-Heymann, N., Okimoto, R.A., Brannigan, B.W., 
Harris, P.L., Driscoll, D.R., Fidias, P., Lynch, T.J., et al. (2005). Irreversible inhibitors of the 
EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A. 
102, 7665-7670. 
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-685. 
Lakshmikuttyamma, A., Pastural, E., Takahashi, N., Sawada, K., Sheridan, D.P., DeCoteau, 
J.F., and Geyer, C.R. (2008). Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 27, 3831-
3844. 
	   74	  
Landon, M.R., Lancia, D.R., Jr., Yu, J., Thiel, S.C., and Vajda, S. (2007). Identification of hot 
spots within druggable binding regions by computational solvent mapping of proteins. J. Med. 
Chem. 50, 1231-1240. 
Levinson, N.M., Kuchment, O., Shen, K., Young, M.A., Koldobskiy, M., Karplus, M., Cole, 
P.A., and Kuriyan, J. (2006). A Src-like inactive conformation in the Abl tyrosine kinase 
domain. PLoS Biol. 4, e144. 
Liao, J.J. (2007a). Molecular recognition of protein kinase binding pockets for design of potent 
and selective kinase inhibitors. J. Med. Chem. 50, 409-424. 
Liao, J.J. (2007b). Molecular targeting of protein kinases to optimize selectivity and resistance 
profiles of kinase inhibitors. Curr. Top. Med. Chem. 7, 1332-1335. 
Liao, J.J., and Andrews, R.C. (2007). Targeting protein multiple conformations: a structure 
based strategy for kinase drug design. Curr. Top. Med. Chem. 7, 1394-1407. 
Lindsley, C.W., Zhao, Z., Leister, W.H., Robinson, R.G., Barnett, S.F., Defeo-Jones, D., Jones, 
R.E., Hartman, G.D., Huff, J.R., Huber, H.E., et al. (2005). Allosteric Akt (PKB) inhibitors: 
discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761-764. 
Liu, Y., and Gray, N.S. (2006). Rational design of inhibitors that bind to inactive kinase 
conformations. Nat. Chem. Biol. 2, 358-364. 
Liu, Y., Shah, K., Yang, F., Witucki, L., and Shokat, K.M. (1998). A molecular gate which 
controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 
6, 1219-1226. 
Lorsch, J.R., and Szostak, J.W. (1996). Chance and necessity in the selection of nucleic acid 
catalysts. Acc Chem. Res. 29, 103-110. 
Ma, H., Kunes, S., Schatz, P.J., and Botstein, D. (1987). Plasmid construction by homologous 
recombination in yeast. Gene 58, 201-216. 
Malumbres, M., and Barbacid, M. (2007). Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 
17, 60-65. 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The protein 
kinase complement of the human genome. Science 298, 1912-1934. 
Martel, V., Filhol, O., Colas, P., and Cochet, C. (2006). p53-dependent inhibition of 
mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory 
subunit of protein kinase CK2. Oncogene 25, 7343-7353. 
McConnell, S.J., Kendall, M.L., Reilly, T.M., and Hoess, R.H. (1994). Constrained peptide 
libraries as a tool for finding mimotopes. Gene 151, 115-118. 
McIntyre, K.W., Shuster, D.J., Gillooly, K.M., Dambach, D.M., Pattoli, M.A., Lu, P., Zhou, 
X.D., Qiu, Y., Zusi, F.C., and Burke, J.R. (2003). A highly selective inhibitor of I kappa B 
kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced 
	   75	  
arthritis in mice. Arthritis. Rheum. 48, 2652-2659. 
McLafferty, M.A., Kent, R.B., Ladner, R.C., and Markland, W. (1993). M13 bacteriophage 
displaying disulfide-constrained microproteins. Gene 128, 29-36. 
McWhirter, J.R., Galasso, D.L., and Wang, J.Y. (1993). A coiled-coil oligomerization domain 
of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13, 
7587-7595. 
Melnikova, I., and Golden, J. (2004). Targeting protein kinases. Nat. Rev. Drug Discov. 3, 993-
994. 
Miller, R.A., Binkowski, B.F., and Belshaw, P.J. (2007). Ligand-regulated peptide aptamers 
that inhibit the 5'-AMP-activated protein kinase. J. Mol. Biol. 365, 945-957. 
Morphy, R. (2010). Selectively nonselective kinase inhibition: striking the right balance. J. 
Med. Chem. 53, 1413-1437. 
Muller, G. (2000). Peptidomimetics SH2 domain antagonists for targeting signal transduction. 
Topics Curr. Chem. 211, 17-59. 
Nagar, B., Hantschel, O., Young, M.A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., 
Superti-Furga, G., and Kuriyan, J. (2003). Structural basis for the autoinhibition of c-Abl 
tyrosine kinase. Cell 112, 859-871. 
Naumann, T.A., Savinov, S.N., and Benkovic, S.J. (2005). Engineering an affinity tag for 
genetically encoded cyclic peptides. Biotechnol. Bioeng. 92, 820-830. 
Noble, M.E., Endicott, J.A., and Johnson, L.N. (2004). Protein kinase inhibitors: insights into 
drug design from structure. Science 303, 1800-1805. 
Nolen, B., Taylor, S., and Ghosh, G. (2004). Regulation of protein kinases; controlling activity 
through activation segment conformation. Mol. Cell. 15, 661-675. 
Nouvion, A.L., Thibaut, J., Lohez, O.D., Venet, S., Colas, P., Gillet, G., and Lalle, P. (2007). 
Modulation of Nr-13 antideath activity by peptide aptamers. Oncogene 26, 701-710. 
O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, 
S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W., et al. (2005). In vitro activity of Bcr-Abl 
inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase 
domain mutants. Cancer Res. 65, 4500-4505. 
Ohren, J.F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, 
P., Spessard, C., Banotai, C., et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) 
and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-
1197. 
Okram, B., Nagle, A., Adrian, F.J., Lee, C., Ren, P., Wang, X., Sim, T., Xie, Y., Xia, G., 
Spraggon, G., et al. (2006). A general strategy for creating "inactive-conformation" Abl 
inhibitors. Chem. Biol. 13, 779-786. 
	   76	  
Parang, K., and Cole, P.A. (2002). Designing bisubstrate analog inhibitors for protein kinases. 
Pharmacol. Ther. 93, 145-157. 
Parang, K., and Sun, G. (2005). Protein kinase inhibitors in drug discovery. In Drug discovery 
handbook, S.C. Gad, ed. (Hoboken, NJ: John Wiley & Sons, Inc.), pp.1191–1258. 
Parikh, M.R., and Matsumura, I. (2005). Site-saturation mutagenesis is more efficient than 
DNA shuffling for the directed evolution of beta-fucosidase from beta-galactosidase. J. Mol. 
Biol. 352, 621-628. 
Pendergast, A.M. (2002). The Abl family kinases: mechanisms of regulation and signaling. 
Adv. Cancer Res. 85, 51-100. 
Perez de Castro, I., de Carcer, G., and Malumbres, M. (2007). A census of mitotic cancer 
genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28, 899-912. 
Reetz, M.T., Prasad, S., Carballeira, J.D., Gumulya, Y., and Bocola, M. (2010). Iterative 
saturation mutagenesis accelerates laboratory evolution of enzyme stereoselectivity: rigorous 
comparison with traditional methods. J. Am. Chem. Soc. 132, 9144-9152. 
Saar, K., Lindgren, M., Hansen, M., Eiriksdottir, E., Jiang, Y., Rosenthal-Aizman, K., Sassian, 
M., and Langel, U. (2005). Cell-penetrating peptides: a comparative membrane toxicity study. 
Anal. Biochem. 345, 55-65. 
Samanta, A., Perazzona, B., Chakraborty, S., Sun, X., Modi, H., Bhatia, R., Priebe, W., and 
Arlinghaus, R. (2011). Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. 
Leukemia 25, 463-472. 
Schmidt, S., Diriong, S., Mery, J., Fabbrizio, E., and Debant, A. (2002). Identification of the 
first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio. 
FEBS Lett. 523, 35-42. 
Scott, C.P., Abel-Santos, E., Jones, A.D., and Benkovic, S.J. (2001). Structural requirements 
for the biosynthesis of backbone cyclic peptide libraries. Chem. Biol. 8, 801-815. 
Scott, C.P., Abel-Santos, E., Wall, M., Wahnon, D.C., and Benkovic, S.J. (1999). Production of 
cyclic peptides and proteins in vivo. Proc. Natl. Acad. Sci. U. S. A. 96, 13638-13643. 
Seeliger, M.A., Young, M., Henderson, M.N., Pellicena, P., King, D.S., Falick, A.M., and 
Kuriyan, J. (2005). High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. 
Protein Sci. 14, 3135-3139. 
Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., and Sawyers, C.L. (2004). Overriding 
imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401. 
Smith, J.M., and Mayer, B.J. (2002). Abl: mechanisms of regulation and activation. Front. 
Biosci. 7, d31-d42. 
Sperandio, O., Miteva, M.A., Segers, K., Nicolaes, G.A., and Villoutreix, B.O. (2008). 
Screening outside the catalytic site: inhibition of macromolecular interactions through structure 
	   77	  
based virtual ligand screening experiments. Open Biochem. J. 2, 29-37. 
Steelman, L.S., Pohnert, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E., and McCubrey, 
J.A. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression 
and leukemogenesis. Leukemia 18, 189-218. 
Taylor, S.S., and Kornev, A.P. (2011). Protein kinases: evolution of dynamic regulatory 
proteins. Trends. Biochem. Sci. 36, 65-77. 
Tecle, H., Shao, J., Li, Y., Kothe, M., Kazmirski, S., Penzotti, J., Ding, Y.H., Ohren, J., 
Moshinsky, D., Coli, R., et al. (2009). Beyond the MEK-pocket: can current MEK kinase 
inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in 
kinases other than MEK? Bioorg. Med. Chem. Lett. 19, 226-229. 
Vagner, J., Qu, H., and Hruby, V.J. (2008). Peptidomimetics, a synthetic tool of drug 
discovery. Curr. Opin. Chem. Biol. 12, 292-296. 
Vu, C.B. (2000). Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 
and ZAP-70. Curr. Med. Chem. 7, 1081-1100. 
Wang, J.Y. (2004). Controlling Abl: auto-inhibition and co-inhibition? Nat. Cell. Biol. 6, 3-7. 
Wang, J.Y., Wilcoxen, K.M., Nomoto, K., and Wu, S. (2007). Recent advances of MEK 
inhibitors and their clinical progress. Curr. Top. Med. Chem. 7, 1364-1378. 
Wei, G., Rafiyath, S., and Liu, D. (2010). First-line treatment for chronic myeloid leukemia: 
dasatinib, nilotinib, or imatinib. J. Hematol. Oncol. 3, 47. 
Weinstein, I.B., and Joe, A.K. (2006). Mechanisms of disease: Oncogene addiction-a rationale 
for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457. 
Wertman, K.F., Wyman, A.R., and Botstein, D. (1986). Host/vector interactions that affect the 
viability of recombinant phage lambda clones. Gene 49, 253-262. 
Wojcik, J., Hantschel, O., Grebien, F., Kaupe, I., Bennett, K.L., Barkinge, J., Jones, R.B., 
Koide, A., Superti-Furga, G., and Koide, S. (2010). A potent and highly specific FN3 
monobody inhibitor of the Abl SH2 domain. Nat. Struct. Mol. Biol. 17, 519-527. 
Wong, T.S., Zhurina, D., and Schwaneberg, U. (2006). The diversity challenge in directed 
protein evolution. Comb. Chem. High Throughput. Screen. 9, 271-288. 
Woodman, R., Yeh, J.T., Laurenson, S., and Ko Ferrigno, P. (2005). Design and validation of a 
neutral protein scaffold for the presentation of peptide aptamers. J. Mol. Biol. 352, 1118-1133. 
Wu, S.Y., McNae, I., Kontopidis, G., McClue, S.J., McInnes, C., Stewart, K.J., Wang, S., 
Zheleva, D.I., Marriage, H., Lane, D.P., et al. (2003). Discovery of a novel family of CDK 
inhibitors with the program LIDAEUS: structural basis for ligand induced disordering of the 
activation loop. Structure 11, 399-410. 
Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M.B., Smithgall, T.E., and Arlinghaus, R.B. (2001). 
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-
	   78	  
6195. 
Young, M.A., Shah, N.P., Chao, L.H., Seeliger, M., Milanov, Z.V., Biggs, W.H., 3rd, Treiber, 
D.K., Patel, H.K., Zarrinkar, P.P., Lockhart, D.J., et al. (2006). Structure of the kinase domain 
of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. 
Cancer Res. 66, 1007-1014. 
Zhang, J., Adrian, F.J., Jahnke, W., Cowan-Jacob, S.W., Li, A.G., Iacob, R.E., Sim, T., Powers, 
J., Dierks, C., Sun, F., et al. (2010). Targeting Bcr-Abl by combining allosteric with ATP 
binding site inhibitors. Nature 463, 501-506. 
Zhang, J., Yang, P.L., and Gray, N.S. (2009). Targeting cancer with small molecule kinase 
inhibitors. Nat. Rev. Cancer 9, 28-39. 
Zhang, X., Subrahmanyam, R., Wong, R., Gross, A.W., and Ren, R. (2001). The NH2 terminal 
coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative 
disease in mice by Bcr-Abl. Mol. Cell. Biol. 21, 840-853. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   79	  
8. Appendices 
Appendix 1 
 
 
 
Lariat peptides against Hck SH1: The A1 lariat was isolated by screening a random 7-mer 
library (Ssp-Ssp R7) against Abl SH1. The noose region of the A1 lariat was subjected to PCR 
random mutagenesis and second position randomization to construct PRM R9 library and CRC 
R9 library, respectively. These second generation libraries were screened against Hck SH1 to 
obtain anti Hck lariats based on the A1 lariat. The WT residues of the A1 lariat are shown in 
red and the amino acid substitutions are shown in blue. A completely random 10-mer library 
(Ssp-Npu R10) was also screened against Hck SH1, which gave rise to two anti Hck lariats 
whose residues are shown in green. 
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Appendix 2 
 
                                     
 
Binding mode of the TG17 lariat: The catalytic cleft of Abl kinase, which is indicated by a 
black rectangle in the figure, contains adenine, ribose, triphosphate and allosteric drug-binding 
pockets. The TG17 lariat predominantly occupies the allosteric region, while the catalytic cleft 
is in the active conformation. The kinase domain of Abl is shown in cartoon representation and 
the inhibitors are drawn as sticks. The N- and C- lobes of the kinase are colored blue and red, 
respectively. The top 15 “docked” conformations of the TG17 lariat obtained from modeling 
studies using three different programs are shown as tricolored sticks. VX-680 (colored green), a 
type I small molecule inhibitor, which occupies the adenine-binding pocket of Abl SH1 is also 
shown. 
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Appendix 3 
 
               
 
Abl SH1 residues that are involved in protein-ligand interactions: Eight different ligands 
that interact with the catalytic cleft of Abl SH1 are included in the figure. Imatinib, nilotinib, 
ponatinib and DCC2036 are type II small molecule inhibitors. Dasatinib and VX-680 are type I 
small molecule inhibitors. The residues that interact with ATP, type II inhibitors, type I 
inhibitors and the TG17 lariat are highlighted in grey, yellow, green, and cyan, respectively. 
The TG17 lariat binds predominantly to the allosteric region and has identified new residues for 
rational drug design, which have not been exploited by other type I or type II inhibitors. In the 
ATP binding pocket, the TG17 lariat makes contacts with residues that are involved in ribose 
and triphosphate binding but not with residues that are involved in adenine binding.  
